US20100143533A1 - Nutritional supplement system - Google Patents
Nutritional supplement system Download PDFInfo
- Publication number
- US20100143533A1 US20100143533A1 US12/699,798 US69979810A US2010143533A1 US 20100143533 A1 US20100143533 A1 US 20100143533A1 US 69979810 A US69979810 A US 69979810A US 2010143533 A1 US2010143533 A1 US 2010143533A1
- Authority
- US
- United States
- Prior art keywords
- vitamin
- dosage unit
- nutrients
- stomach
- nutritional supplement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 106
- 235000015097 nutrients Nutrition 0.000 claims abstract description 142
- 210000002784 stomach Anatomy 0.000 claims abstract description 132
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 117
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 117
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 115
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 115
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 52
- 210000000936 intestine Anatomy 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims description 66
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 58
- 239000003826 tablet Substances 0.000 claims description 58
- 238000013268 sustained release Methods 0.000 claims description 47
- 239000012730 sustained-release form Substances 0.000 claims description 47
- 235000019154 vitamin C Nutrition 0.000 claims description 30
- 239000011718 vitamin C Substances 0.000 claims description 30
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 29
- 229930003268 Vitamin C Natural products 0.000 claims description 29
- 239000007894 caplet Substances 0.000 claims description 28
- 229940088594 vitamin Drugs 0.000 claims description 28
- 229930003231 vitamin Natural products 0.000 claims description 28
- 239000011782 vitamin Substances 0.000 claims description 28
- 230000037406 food intake Effects 0.000 claims description 26
- 239000004615 ingredient Substances 0.000 claims description 26
- 235000013343 vitamin Nutrition 0.000 claims description 26
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 24
- 230000036470 plasma concentration Effects 0.000 claims description 24
- 239000006041 probiotic Substances 0.000 claims description 24
- 235000018291 probiotics Nutrition 0.000 claims description 24
- 239000013589 supplement Substances 0.000 claims description 22
- 235000019156 vitamin B Nutrition 0.000 claims description 22
- 239000011720 vitamin B Substances 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 21
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 21
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 21
- 239000011707 mineral Substances 0.000 claims description 21
- 235000010755 mineral Nutrition 0.000 claims description 19
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 17
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 16
- 230000029087 digestion Effects 0.000 claims description 15
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 14
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 14
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 14
- 229960002477 riboflavin Drugs 0.000 claims description 14
- 239000011575 calcium Substances 0.000 claims description 13
- 235000019152 folic acid Nutrition 0.000 claims description 13
- 239000011724 folic acid Substances 0.000 claims description 13
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 13
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 13
- 238000010521 absorption reaction Methods 0.000 claims description 12
- 238000005538 encapsulation Methods 0.000 claims description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 11
- 229930003471 Vitamin B2 Natural products 0.000 claims description 11
- 239000006014 omega-3 oil Substances 0.000 claims description 11
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 11
- 235000019164 vitamin B2 Nutrition 0.000 claims description 11
- 239000011716 vitamin B2 Substances 0.000 claims description 11
- 235000019158 vitamin B6 Nutrition 0.000 claims description 11
- 239000011726 vitamin B6 Substances 0.000 claims description 11
- 229940011671 vitamin b6 Drugs 0.000 claims description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 10
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 10
- 229930003451 Vitamin B1 Natural products 0.000 claims description 10
- 229910052791 calcium Inorganic materials 0.000 claims description 10
- 235000001465 calcium Nutrition 0.000 claims description 10
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 10
- 235000021323 fish oil Nutrition 0.000 claims description 10
- 229960003495 thiamine Drugs 0.000 claims description 10
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 10
- 235000010374 vitamin B1 Nutrition 0.000 claims description 10
- 239000011691 vitamin B1 Substances 0.000 claims description 10
- 230000004071 biological effect Effects 0.000 claims description 9
- 229960002079 calcium pantothenate Drugs 0.000 claims description 9
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 claims description 9
- 235000019165 vitamin E Nutrition 0.000 claims description 9
- 239000011709 vitamin E Substances 0.000 claims description 9
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 8
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 8
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 8
- 229930003571 Vitamin B5 Natural products 0.000 claims description 8
- 229960000304 folic acid Drugs 0.000 claims description 8
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 8
- 235000009492 vitamin B5 Nutrition 0.000 claims description 8
- 239000011675 vitamin B5 Substances 0.000 claims description 8
- 239000011647 vitamin D3 Substances 0.000 claims description 8
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 8
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 7
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 7
- 229930003427 Vitamin E Natural products 0.000 claims description 7
- 230000002411 adverse Effects 0.000 claims description 7
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 7
- 235000016709 nutrition Nutrition 0.000 claims description 7
- 235000005875 quercetin Nutrition 0.000 claims description 7
- 229960001285 quercetin Drugs 0.000 claims description 7
- 210000000813 small intestine Anatomy 0.000 claims description 7
- 229940046009 vitamin E Drugs 0.000 claims description 7
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 6
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 6
- 229910052796 boron Inorganic materials 0.000 claims description 6
- 229910052804 chromium Inorganic materials 0.000 claims description 6
- 239000011651 chromium Substances 0.000 claims description 6
- 229960003512 nicotinic acid Drugs 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 6
- 235000019198 oils Nutrition 0.000 claims description 6
- 239000011669 selenium Substances 0.000 claims description 6
- 229910052711 selenium Inorganic materials 0.000 claims description 6
- 235000019155 vitamin A Nutrition 0.000 claims description 6
- 239000011719 vitamin A Substances 0.000 claims description 6
- 235000005282 vitamin D3 Nutrition 0.000 claims description 6
- 229940021056 vitamin d3 Drugs 0.000 claims description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 5
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 5
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 5
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 5
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 5
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 5
- 229930003448 Vitamin K Natural products 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- 229960004308 acetylcysteine Drugs 0.000 claims description 5
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 5
- 235000013734 beta-carotene Nutrition 0.000 claims description 5
- 239000011648 beta-carotene Substances 0.000 claims description 5
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 5
- 229960002747 betacarotene Drugs 0.000 claims description 5
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 239000010949 copper Substances 0.000 claims description 5
- 229910052802 copper Inorganic materials 0.000 claims description 5
- 229940014144 folate Drugs 0.000 claims description 5
- 235000010382 gamma-tocopherol Nutrition 0.000 claims description 5
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 5
- 239000001751 lycopene Substances 0.000 claims description 5
- 235000012661 lycopene Nutrition 0.000 claims description 5
- 229960004999 lycopene Drugs 0.000 claims description 5
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 5
- 229910052750 molybdenum Inorganic materials 0.000 claims description 5
- 239000011733 molybdenum Substances 0.000 claims description 5
- 229910052759 nickel Inorganic materials 0.000 claims description 5
- 239000011574 phosphorus Substances 0.000 claims description 5
- 229910052698 phosphorus Inorganic materials 0.000 claims description 5
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 5
- 239000003531 protein hydrolysate Substances 0.000 claims description 5
- 239000010703 silicon Substances 0.000 claims description 5
- 229910052710 silicon Inorganic materials 0.000 claims description 5
- 229910052718 tin Inorganic materials 0.000 claims description 5
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 5
- 229910052720 vanadium Inorganic materials 0.000 claims description 5
- 239000011712 vitamin K Substances 0.000 claims description 5
- 235000019168 vitamin K Nutrition 0.000 claims description 5
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 5
- 229940046010 vitamin k Drugs 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 5
- 239000002478 γ-tocopherol Substances 0.000 claims description 5
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 claims description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- 235000012680 lutein Nutrition 0.000 claims description 4
- 239000001656 lutein Substances 0.000 claims description 4
- 229960005375 lutein Drugs 0.000 claims description 4
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 4
- 239000011135 tin Substances 0.000 claims description 4
- 239000011573 trace mineral Substances 0.000 claims description 4
- 235000013619 trace mineral Nutrition 0.000 claims description 4
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 4
- 229940045997 vitamin a Drugs 0.000 claims description 4
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 4
- 229930003537 Vitamin B3 Natural products 0.000 claims description 3
- 238000009501 film coating Methods 0.000 claims description 3
- 239000007888 film coating Substances 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 3
- 235000019160 vitamin B3 Nutrition 0.000 claims description 3
- 239000011708 vitamin B3 Substances 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 229940055726 pantothenic acid Drugs 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 239000011713 pantothenic acid Substances 0.000 claims description 2
- 239000007942 layered tablet Substances 0.000 claims 3
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 description 27
- 238000000576 coating method Methods 0.000 description 24
- 239000011248 coating agent Substances 0.000 description 20
- 239000002775 capsule Substances 0.000 description 16
- 239000010410 layer Substances 0.000 description 16
- 239000001856 Ethyl cellulose Substances 0.000 description 15
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 15
- 229920001249 ethyl cellulose Polymers 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 235000019325 ethyl cellulose Nutrition 0.000 description 13
- 108010010803 Gelatin Proteins 0.000 description 10
- 239000008273 gelatin Substances 0.000 description 10
- 229920000159 gelatin Polymers 0.000 description 10
- 229940014259 gelatin Drugs 0.000 description 10
- 235000019322 gelatine Nutrition 0.000 description 10
- 235000011852 gelatine desserts Nutrition 0.000 description 10
- 230000000529 probiotic effect Effects 0.000 description 10
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 9
- 235000010413 sodium alginate Nutrition 0.000 description 9
- 239000000661 sodium alginate Substances 0.000 description 9
- 229940005550 sodium alginate Drugs 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 229940029329 intrinsic factor Drugs 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- -1 or other elements Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 235000015424 sodium Nutrition 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 6
- 150000003722 vitamin derivatives Chemical class 0.000 description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 235000010419 agar Nutrition 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229920002301 cellulose acetate Polymers 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 238000009505 enteric coating Methods 0.000 description 4
- 239000002702 enteric coating Substances 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 239000004816 latex Substances 0.000 description 4
- 229920000126 latex Polymers 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 235000020786 mineral supplement Nutrition 0.000 description 4
- 235000010987 pectin Nutrition 0.000 description 4
- 229920001277 pectin Polymers 0.000 description 4
- 239000001814 pectin Substances 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 244000060011 Cocos nucifera Species 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 206010000059 abdominal discomfort Diseases 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002662 enteric coated tablet Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 229920001477 hydrophilic polymer Polymers 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 210000003405 ileum Anatomy 0.000 description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 239000011785 micronutrient Substances 0.000 description 3
- 235000013369 micronutrients Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000019192 riboflavin Nutrition 0.000 description 3
- 239000002151 riboflavin Substances 0.000 description 3
- AEDORKVKMIVLBW-BLDDREHASA-N 3-oxo-3-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methoxy]oxan-2-yl]methoxy]propanoic acid Chemical compound OCC1=C(O)C(C)=NC=C1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CC(O)=O)O1 AEDORKVKMIVLBW-BLDDREHASA-N 0.000 description 2
- DMIMWGHYIPFAIF-UHFFFAOYSA-N 5-nitro-2-piperidin-1-ylaniline Chemical compound NC1=CC([N+]([O-])=O)=CC=C1N1CCCCC1 DMIMWGHYIPFAIF-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 240000008886 Ceratonia siliqua Species 0.000 description 2
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 2
- 244000298479 Cichorium intybus Species 0.000 description 2
- 235000007542 Cichorium intybus Nutrition 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 244000303965 Cyamopsis psoralioides Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- KCXZNSGUUQJJTR-UHFFFAOYSA-N Di-n-hexyl phthalate Chemical compound CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCC KCXZNSGUUQJJTR-UHFFFAOYSA-N 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- MURWRBWZIMXKGC-UHFFFAOYSA-N Phthalsaeure-butylester-octylester Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC MURWRBWZIMXKGC-UHFFFAOYSA-N 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 240000001058 Sterculia urens Species 0.000 description 2
- 235000015125 Sterculia urens Nutrition 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- MGQQZGJIMOVHRZ-UHFFFAOYSA-N [Si].O=O Chemical compound [Si].O=O MGQQZGJIMOVHRZ-UHFFFAOYSA-N 0.000 description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N beta-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 229940047036 calcium ascorbate Drugs 0.000 description 2
- 235000010376 calcium ascorbate Nutrition 0.000 description 2
- 239000011692 calcium ascorbate Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 2
- 229950008138 carmellose Drugs 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 239000011247 coating layer Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 229940029985 mineral supplement Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 235000017802 other dietary supplement Nutrition 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000007939 sustained release tablet Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 235000019149 tocopherols Nutrition 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 229960002622 triacetin Drugs 0.000 description 2
- 125000005591 trimellitate group Chemical group 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 235000019195 vitamin supplement Nutrition 0.000 description 2
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- BJQHLKABXJIVAM-BGYRXZFFSA-N 1-o-[(2r)-2-ethylhexyl] 2-o-[(2s)-2-ethylhexyl] benzene-1,2-dicarboxylate Chemical compound CCCC[C@H](CC)COC(=O)C1=CC=CC=C1C(=O)OC[C@H](CC)CCCC BJQHLKABXJIVAM-BGYRXZFFSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 1
- FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 description 1
- PZBLUWVMZMXIKZ-UHFFFAOYSA-N 2-o-(2-ethoxy-2-oxoethyl) 1-o-ethyl benzene-1,2-dicarboxylate Chemical compound CCOC(=O)COC(=O)C1=CC=CC=C1C(=O)OCC PZBLUWVMZMXIKZ-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 244000017106 Bixa orellana Species 0.000 description 1
- GOJCZVPJCKEBQV-UHFFFAOYSA-N Butyl phthalyl butylglycolate Chemical compound CCCCOC(=O)COC(=O)C1=CC=CC=C1C(=O)OCCCC GOJCZVPJCKEBQV-UHFFFAOYSA-N 0.000 description 1
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-SVZMEOIVSA-N D-fucopyranose Chemical compound C[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O SHZGCJCMOBCMKK-SVZMEOIVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- PGIBJVOPLXHHGS-UHFFFAOYSA-N Di-n-decyl phthalate Chemical compound CCCCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCCCC PGIBJVOPLXHHGS-UHFFFAOYSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- BJQHLKABXJIVAM-UHFFFAOYSA-N Diethylhexyl phthalate Natural products CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229920000896 Ethulose Polymers 0.000 description 1
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 1
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000227647 Fucus vesiculosus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004348 Glyceryl diacetate Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 240000003394 Malpighia glabra Species 0.000 description 1
- 235000014837 Malpighia glabra Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- KRADHMIOFJQKEZ-UHFFFAOYSA-N Tri-2-ethylhexyl trimellitate Chemical compound CCCCC(CC)COC(=O)C1=CC=C(C(=O)OCC(CC)CCCC)C(C(=O)OCC(CC)CCCC)=C1 KRADHMIOFJQKEZ-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- RXRZOKQPANIEDW-KQYNXXCUSA-N [9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]purin-6-yl] dihydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C2=NC=NC(OP(O)(O)=O)=C2N=C1 RXRZOKQPANIEDW-KQYNXXCUSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002998 adhesive polymer Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 235000012665 annatto Nutrition 0.000 description 1
- 239000010362 annatto Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 229940015408 ascorbic acid 120 mg Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- SAOKZLXYCUGLFA-UHFFFAOYSA-N bis(2-ethylhexyl) adipate Chemical compound CCCCC(CC)COC(=O)CCCCC(=O)OCC(CC)CCCC SAOKZLXYCUGLFA-UHFFFAOYSA-N 0.000 description 1
- ZDWGXBPVPXVXMQ-UHFFFAOYSA-N bis(2-ethylhexyl) nonanedioate Chemical compound CCCCC(CC)COC(=O)CCCCCCCC(=O)OCC(CC)CCCC ZDWGXBPVPXVXMQ-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940043430 calcium compound Drugs 0.000 description 1
- 150000001674 calcium compounds Chemical class 0.000 description 1
- 229940088129 calcium pantothenate 10 mg Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229920001727 cellulose butyrate Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229920006218 cellulose propionate Polymers 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940070404 citrus bioflavonoids Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229940072798 copper gluconate 2 mg Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 229940099371 diacetylated monoglycerides Drugs 0.000 description 1
- UCVPKAZCQPRWAY-UHFFFAOYSA-N dibenzyl benzene-1,2-dicarboxylate Chemical compound C=1C=CC=C(C(=O)OCC=2C=CC=CC=2)C=1C(=O)OCC1=CC=CC=C1 UCVPKAZCQPRWAY-UHFFFAOYSA-N 0.000 description 1
- PCYQQSKDZQTOQG-NXEZZACHSA-N dibutyl (2r,3r)-2,3-dihydroxybutanedioate Chemical compound CCCCOC(=O)[C@H](O)[C@@H](O)C(=O)OCCCC PCYQQSKDZQTOQG-NXEZZACHSA-N 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- HBGGXOJOCNVPFY-UHFFFAOYSA-N diisononyl phthalate Chemical compound CC(C)CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCC(C)C HBGGXOJOCNVPFY-UHFFFAOYSA-N 0.000 description 1
- FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 description 1
- 229960001826 dimethylphthalate Drugs 0.000 description 1
- XWVQUJDBOICHGH-UHFFFAOYSA-N dioctyl nonanedioate Chemical compound CCCCCCCCOC(=O)CCCCCCCC(=O)OCCCCCCCC XWVQUJDBOICHGH-UHFFFAOYSA-N 0.000 description 1
- VJHINFRRDQUWOJ-UHFFFAOYSA-N dioctyl sebacate Chemical compound CCCCC(CC)COC(=O)CCCCCCCCC(=O)OCC(CC)CCCC VJHINFRRDQUWOJ-UHFFFAOYSA-N 0.000 description 1
- YCZJVRCZIPDYHH-UHFFFAOYSA-N ditridecyl benzene-1,2-dicarboxylate Chemical compound CCCCCCCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCCCCCCC YCZJVRCZIPDYHH-UHFFFAOYSA-N 0.000 description 1
- QQVHEQUEHCEAKS-UHFFFAOYSA-N diundecyl benzene-1,2-dicarboxylate Chemical compound CCCCCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCCCCC QQVHEQUEHCEAKS-UHFFFAOYSA-N 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229940002880 ferrous fumarate 18 mg Drugs 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000012817 gel-diffusion technique Methods 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 235000019443 glyceryl diacetate Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940069352 hesperidin complex Drugs 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940064987 lemon bioflavonoid Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 229940033274 magnesium oxide 200 mg Drugs 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 239000011683 manganese gluconate Substances 0.000 description 1
- 235000014012 manganese gluconate Nutrition 0.000 description 1
- 229940072543 manganese gluconate Drugs 0.000 description 1
- OXHQNTSSPHKCPB-IYEMJOQQSA-L manganese(2+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Mn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OXHQNTSSPHKCPB-IYEMJOQQSA-L 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000020772 multivitamin supplement Nutrition 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229940095442 niacinamide 100 mg Drugs 0.000 description 1
- 229940089784 niacinamide 20 mg Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 235000021231 nutrient uptake Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940038580 oat bran Drugs 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- JQCXWCOOWVGKMT-UHFFFAOYSA-N phthalic acid diheptyl ester Natural products CCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCC JQCXWCOOWVGKMT-UHFFFAOYSA-N 0.000 description 1
- 229920001390 poly(hydroxyalkylmethacrylate) Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 229940089808 pyridoxine hydrochloride 10 mg Drugs 0.000 description 1
- 229940048011 quercetin 50 mg Drugs 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 229940054678 thiamine mononitrate 1.5 mg Drugs 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940082632 vitamin b12 and folic acid Drugs 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- 229940120611 zinc gluconate 15 mg Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
Definitions
- Described herein is a nutritional supplement system for the delivery of vitamins, minerals, and/or probiotics for sustaining the health of human subjects.
- Vitamin and mineral preparations are commonly administered as general nutritional supplements.
- Micronutrients are elements or compounds which are present in foods and herbs in small or trace amounts. These include vitamins, minerals, or other elements, and substances found in foods.
- the macronutrients consist of carbohydrates, fats, and proteins, which supply nutrients and calories. Some elements such as calcium, sodium, potassium, chloride, and phosphorus are consumed in relatively large amounts, while many such as iron, iodine, and zinc are consumed in small amounts.
- Vitamins, such as vitamin B12 and folic acid, and the minerals copper, selenium, and chromium are consumed in very small or trace amounts.
- probiotic supplements also can be beneficial to the well being of humans. It has been recognized that temporary or chronic digestive symptoms can be caused by a damaged or disordered intestinal flora. Consumption of a nutritional supplement preparation containing suitable microorganisms is often sufficient to alleviate or to eliminate the symptoms caused by a disordered or damaged intestinal flora.
- probiotics refers to live micro-organisms, delivered in food supplements, which beneficially affect the host animal by improving its intestinal microbial balance. Antibiotics and other related compounds are not included in this definition. ( J. Nutr. 1995; 125:1401-12). For humans, lactobacilli are commonly provided as probiotics, either as single species or in mixed culture with other bacteria. Other genera that have been used are bifidobacteria and streptococci . “Prebiotics” refers to non-digestible food ingredients that beneficially affect the host by selectively stimulating the growth and/or activity of bacteria in the colon.
- Prior nutritional supplement systems have in some cases delivered nutrients to a location in the digestive tract where, although effective for uptake of the nutrients, have caused user discomfort. In other cases, one or more nutrients are released in a location that is not optimal for uptake by the body. When nutrients or probiotics are released in locations that are unfavorable reduce biological activity can result. For example, probiotics typically do not survive exposure to stomach acid.
- vitamin B12 is readily absorbed in the last part of the small intestine (ileum), which leads to the large intestine.
- ileum small intestine
- the vitamin must combine with intrinsic factor.
- intrinsic factor As a result of passage through the stomach, vitamin B12 is attaches to intrinsic factor for transfer. This combination of the vitamin and intrinsic factor can then be “caught” by the ileal receptor. Without intrinsic factor, significant amounts of vitamin B12 can remain in the intestine and are excreted in the stool.
- a nutritional supplement system that supplies nutrients and/or probiotics at various appropriate locations in the digestive tract.
- One particular element of such a system is a dosage unit formulated to release vitamin B12 over time in both the stomach and the intestines of the upper GI tract.
- a multi-component oral nutritional supplement system supplies a combination of nutrients and/or probiotics at optimal locations throughout the digestive tract of a human subject for efficient nutrient utilization and user comfort and convenience.
- An optimal system includes four dosage units, although certain other beneficial systems may include two or three dosage units.
- a first dosage unit that is formulated to quickly release one or more nutrients in the stomach of a human subject.
- This dosage unit advantageously includes vitamins and minerals or other dietary supplement ingredients that benefit from release in the stomach and exposure to stomach acid, or are not adversely affected by such release or exposure, and/or properly are dispersed in the stomach for optimal absorption further down in the GI tract.
- This dosage unit advantageously is in the form of a tablet or caplet formed by compression. The tablet may be coated with a layer containing one or more nutrients that best are delivered in the stomach particularly rapidly.
- the first dosage unit should not contain substances that are not well tolerated by the stomach or that would be harmed by the acidic environment of the stomach; such substances should be delivered in one of the other dosage units described herein.
- a second dosage unit is formulated to contain nutrients that do not require release in the stomach and exposure to stomach acid for efficient digestion and absorption, and which may cause tolerance problems (repeating, stomach upset, nausea) or loss in biological activity when released in the stomach.
- This dosage unit advantageously is used to deliver certain nutritional oils, notably fish oil constituents, other omega-3 fatty acid containing oils, and may also include fat-soluble micronutrients that do not require stomach digestion, such as vitamins A, D, E, and carotenoids.
- the dosage unit advantageously is a sealed gelatin encapsulation that can pass through the stomach before releasing the encapsulated nutrients.
- a third dosage unit is formulated to contain water-soluble nutrients and other nutrients that are typically very rapidly absorbed and therefore best delivered by sustained release so as to maintain an elevated concentration in the body over time.
- This dosage unit is designed to slowly, in generally linear fashion, release one or more water-soluble nutrients. The release of these nutrients is initially in the stomach and continues into the intestines of the upper GI tract.
- This dosage unit advantageously is formulated to release vitamin B12. The dosage unit also is useful to deliver other B-vitamins and vitamin C.
- a fourth dosage unit contains nutrients and/or other supplement ingredients such as probiotics that are adversely affected by exposure to stomach acid or stomach digestion, and that should be delivered into the lower parts of the small intestine for full activity in the large intestine.
- This dosage unit is formulated to protect the probiotic microorganisms from potentially lethal acid exposure during passage of the dosage unit through the stomach.
- it is in the form of a three-layer capsule.
- These four dosage units are formulated for administration one time each day, and can be taken substantially simultaneously, to provide complete and appropriately timed delivery of a full range of nutrients and probiotics.
- All the dosage units of complete daily dose of the nutritional supplement system advantageously are packaged together as a multi-element package so that a user will not need to remember to combine various individual dosage units to make a complete daily dose.
- certain of the dosage units can be split into two or more tablets, caplets, or capsules.
- the first dosage unit is in the form of two separate dosage elements, preferably tablets or caplets
- the second dosage unit is in the form of two separate dosage elements, preferably gel encapsulations.
- the two first dosage unit elements, the two second dosage unit elements, one third dosage unit element, and one fourth dosage unit element can be provided together, for example in a single blister pack card or strip, so that a user will immediately know that the six elements together are a day's dose.
- a typical blister pack arrangement will have six attached blister strips, separated by perforated detachment lines, with each strip holding the six dosage elements that together comprise a day's dose.
- the dosage units advantageously employ various forms of extended release excipients or coatings along with immediate release excipients or coatings to deliver the various vitamins and mineral supplements over various optimum rates of release.
- a folic acid micro-coating can be employed to release folic acid from the multi-vitamin and mineral supplement within minutes after entry into the stomach.
- Gel diffusion technology can be used to maximize the intestinal adsorption of vitamins B and C for over twelve hours.
- Providing fish oil in delayed release capsules results in rapid release in the intestines of upper GI tract, which gives maximum bioavailability and minimum stomach discomfort.
- a triple layer encapsulation system provides for targeted release of probiotics to the lower GI tract.
- Nutritional supplement dosage units may employ one or more forms of release, including, without limitation, immediate release, extended release, pulse release, variable release, controlled release, timed release, sustained release, delayed release, long acting, and combinations thereon.
- the various types of release can be accomplished using well known procedures and techniques.
- the time release characteristics for the release of the components may be varied by modifying the composition of layers, including modifying any of the excipients or coatings which may be present. For example, changing the composition or amount of the covering or coating layers may be used to control the release of the components. Similarly, when modified release is facilitated by the inclusion of a specific matrix material, controlling the choice and amount of modified release matrix material utilized may be used to control the release of the active components.
- the matrix material may be present, either surrounding individual components of the composition or over a layer of the composition, in any amount that is sufficient to yield the desired time release or time lag between release of the components.
- coating materials suitable for use in the practice include, but are not limited to polymer coating materials, hydrogels and gel-forming materials and hydrophilic polymers.
- Preferred polymer coating materials are cellulose acetate phthalate, cellulose acetate trimaletate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, amino methacrylate copolymers such as Eudragit® RS and RL, polyacrylic acid and polyacrylate and methacrylate copolymers such as Eudragit® S and L, polyvinyl acetaldiethylamino acetate, hydroxypropyl methylcellulose acetate succinate, and shellac.
- Preferred hydrogels and gel-forming materials include carboxyvinyl polymers, sodium alginate, sodium carmellose, calcium carmellose, sodium carboxymethyl starch, polyvinyl alcohol, hydroxyethyl cellulose, methyl cellulose, gelatin, starch, and cellulose based cross-linked polymers in which the degree of crosslinking is low so as to facilitate adsorption of water and expansion of the polymer matrix, hydroxypropyl cellulose, hydroxypropyl methylcellulose, crosslinked starch, microcrystalline cellulose, chitin, aminoacryl-methacrylate copolymer (Eudragit® RS-PM), pullulan, collagen, casein, agar, gum arabic, sodium carboxymethyl cellulose, (swellable hydrophilic polymers) poly(hydroxyalkyl methacrylate) (molecular weight about 5 k-5,000 k), polyvinylpyrrolidone (molecular weight about 10 k-360 k), anionic and cationic hydrogels, polyviny
- Preferred hydrophilic polymers include polysaccharides, methyl cellulose, sodium or calcium carboxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, nitrocellulose, carboxymethyl cellulose, cellulose ethers, polyethylene oxides (e.g.
- Polyox® Union Carbide
- plasticisers such as plasticisers, lubricants, solvents and the like may be added to a coating.
- Suitable plasticisers include for example hydroxylated soy lecithin, acetylated monoglycerides, butyl phthalyl butyl glycolate, dibutyl tartrate, diethyl phthalate, dimethyl phthalate, ethyl phthalyl ethyl glycolate, glycerin, propylene glycol, triacetin, citrate, tripropioin, diacetin, dibutyl phthalate, acetyl monoglyceride, polyethylene glycols, castor oil, triethyl citrate, polyhydric alcohols, glycerol, acetate esters, glycerol triacetate, acetyl triethyl citrate, dibenzyl phthalate, dihexyl phthalate, butyl octyl phthalate, diisonony
- a coating layer may be any suitable modified release matrix material or suitable combination of modified release matrix materials. Such materials are known to those skilled in the art.
- Modified release matrix materials suitable for the practice of the present invention include, but are not limited to, microcrystalline cellulose, sodium carboxymethylcellulose, hydroxyalkylcelluloses (e.g., hydroxypropylmethylcellulose and hydroxypropylcellulose), polyethylene oxide, alkylcelluloses (e.g., methylcellulose and ethylcellulose), polyethylene glycol, polyvinylpyrrolidone, cellulose acetate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose acetate trimellitate, polyvinylacetate phthalate, polyalkylmethacrylates, polyvinyl acetate and mixtures thereof.
- the dissolution characteristics of a dosage form can be manipulated not only through the quantity of the excipients in the finished dosage form and size of the finished dosage form, but also by a judicious selection and blending of various molecular weights of a given polymer or polymers, as is known to those skilled in the art.
- Film coated tablets may be prepared by coating tablets using techniques such as rotating pan coating methods or air suspension methods to deposit a contiguous film layer on a tablet. This procedure is often done to improve the aesthetic appearance of tablets, but may also be done to improve the swallowing of tablets, to mask an obnoxious odor or taste, or to improve to usual properties of an unsightly uncoated tablet.
- Compressed tablets for example, without limitation, may be prepared by mixing the components with excipients intended to add binding or disintegration qualities. The mixture is either directly compressed, or granulated then compressed, using methods and machinery quite well known to those in the industry.
- Example prebiotics include oligosaccharides such as glucose, fructose, xylose, galactose, lactose, mannose, arabinose, D-fucose, L-fucose, rhamnose, Actilight, Biotose, Palatinose, IMO, cellobiose, gentiobiose, laevan, maltodextrin, maltose, melibiose, raffinose, lactose, panorich, melezitose, raftiline, raftilose, stachyose, sucrose, tagatose, xylan, fructooligosaccharide (FOS), galactooligosaccharide (GOS), soy oligosaccharide, lactosucrose, maltooligosaccharide, xylooligos
- oligosaccharides such as glucose, fructose, xylose, gal
- the first dosage unit is formulated to contain vitamins and minerals, typically at or near their USFDA Daily Value (DV) level, that best are delivered in the stomach.
- vitamins and minerals typically at or near their USFDA Daily Value (DV) level, that best are delivered in the stomach.
- Such nutrients include vitamins, minerals and other dietary supplement ingredients that benefit from release in the stomach and exposure to stomach acid, or that are not adversely affected by such release or exposure, and/or that properly are dispersed in the stomach for optimal absorption further down the GI tract.
- This dosage unit advantageously is in the form of a tablet or caplet formed by compression of a blend containing vitamins, minerals and appropriate excipients. Because rapid delivery of nutrients is desired, the first dosage unit should be formulated for release in less than one hour, and best within 0.75 hour.
- the tablet or caplet may be coated with a layer containing one or more nutrients that best are delivered particularly rapidly.
- the coating will include folic acid (folate) for rapid release.
- folic acid fluoride
- folic acid in an outer coating is released more rapidly than when folic acid is contained in the core of a tablet, resulting in increased bioavailability.
- the first dosage unit optimally is formulated to include:
- Example formulations of a first nutritional supplement dosage unit, in the form of immediate release tablets, are shown in the following table:
- Coated tablets were assembled by combining the ingredients to form the blend for a core and compressing the blend to form tablets. The tablets were then coated with a film coating solution. Two such tablets served as one day's dose of the first dosage unit.
- the second dosage unit is formulated to contain nutrients that do not require release in the stomach and exposure to stomach acid for efficient digestion and absorption, and which may cause tolerance problems (repeating, stomach upset, nausea) or loss in biological activity when released in the stomach.
- This dosage unit advantageously is used to deliver certain nutritional oils, notably fish oil constituents, other omega-3 fatty acid containing oils, and may also include fat-soluble micronutrients that do not require stomach digestion, such as vitamins A, D, E, and carotenoids.
- the dosage unit advantageously is a sealed gelatin encapsulation that can pass through the stomach before releasing the encapsulated nutrients.
- This dosage unit is formulated to pass through the stomach without releasing its contents, notably fish oil, and remain unopened until after it naturally passes into the intestines of the upper GI tract. Release in the stomach can lead to an unpleasant taste caused by repeating fish oil aroma (“fish burp”) in the mouth of a user.
- fish burp repeating fish oil aroma
- This dosage form thus advantageously is a soft capsule having a coating resistant to gastric juice to achieve a delayed release of the fish oil in the intestine, advantageously a coating of a polymer such as methacrylic acid. Delayed release can also be accomplished or enhanced by cross-linking of gelatin used to form such a capsule or by providing derivates of starch in the casing of such a capsule.
- the second dosage unit optimally is formulated to include:
- Lutein ester suspension 2 mg Lycopene suspension 2.5 mg Vitamin D 3 200 IU Mixed tocotrienols & tocopherols 1 mg Vitamin E (a-tocopherol 140 IU concentrate) Total omega-3 fatty acids 500 mg Gamma tocopherol 25 mg Beta and delta tocopherol 10 mg Silicon dioxide n/a Beeswax n/a Glycerin n/a Gelatin n/a Annatto suspension (Ultrabix n/a 03190) Water n/a Enteric coating (TM29Z19241 n/a Clear) Surelease (E-7-19040) n/a Natural vanillin n/a
- the nutritional ingredients were mixed to form a fill mixture.
- Gel mass ingredients were mixed to form a gel mass.
- Formed halves were injected with the fill mixture and then joined to form capsules.
- Coating ingredients were mixed to make a coating mixture; and then the formed capsules were coated with the mixture in a tablet coating apparatus. The finished product was then dried.
- Two of the resulting encapsulations served as one day's dose of the second dosage unit.
- the third dosage unit is formulated to contain one or more water-soluble nutrients and/or other nutrients that are typically very rapidly absorbed and therefore best delivered by sustained release so as to maintain an elevated concentration in the body over time.
- Certain rapidly-absorbed, typically water-soluble nutrients are best delivered by sustained release so as to maintain an elevated concentration in the body over time. These include B-vitamins and vitamin C. If given in an immediate release dosage unit, the concentrations of such vitamins in the body rapidly decline after an initial peak. Moreover, the absorptive sites and nutrient uptake mechanisms in the intestinal wall can be overwhelmed by the high intestinal nutrient concentrations caused by immediate release dosage units, which is known to reduce the overall amount that can be taken up by the body. Sustained release dosage units of such vitamins have been used to overcome these problems. But sustained release dosage units of such vitamins have typically excluded vitamin B12 because of the perceived need to deliver an entire dose of vitamin B12 to the stomach so that it can be combined with intrinsic factor.
- vitamin B12 delivered by sustained release, can result in improved bioavailability of vitamin B12 as compared to immediate release in the stomach.
- subjects were given a tablet containing 9.8 mg vitamin B1, 11.5 mg vitamin B2, 13.1 mg vitamin B6, 90 ⁇ g vitamin B12 and 518 mg vitamin C.
- B vitamins ingestion of a comparable immediate-release formulation produced peak plasma concentrations for B1, B2 and B6 at 2 hours post ingestion and at 3 hours for serum vitamin B12. B-vitamin concentrations then declined rapidly from peak concentrations, returning to baseline by 6 hr for B1 and B6 and by 12 hr for B2 and B12.
- sustained release tablet delivery was found to improve the bioavailability of vitamin C and at least three B-vitamins, including vitamin B12, in comparison to immediate release delivery.
- the third dosage unit thus is formulated to release vitamin B12 in the stomach and intestines of the upper GI tract, advantageously in an amount that is greater than or at multiple levels of the DV (Daily Value) of vitamin B12. This is accomplished by including vitamin B12 in an amount of from 3 mcg to 500 mcg, with best results at a vitamin B12 amount of from 6 mcg to 500 mcg.
- Best results for the delivery of vitamin B12 are achieved with a dosage unit that releases vitamin B12, as determined by USP dissolution apparatus at 37° C. at 50 RPM paddle speed in 900 ml of 0.1N HCl, continuously and generally linearly over a period of 6 hours. It is particularly advantageous for the dosage unit to be formulated to allow at least 15% of the vitamin B12 to dissolve in one hour in 900 ml of 0.1N HCl at 37° C. This dosage form, after ingestion by a subject, will sustain plasma levels of the vitamin B12 for a period 12 hours.
- vitamin B12 is achieved, for example, with third dosage unit tablet of 350 mg to 1500 mg total weight, where the tablet contains 20 mcg to 100 mcg of vitamin B12 and contains 5% to 20% HPMC K100/E15 by weight. Superior results are achieved with tablets having 9.5% to 14% HPMC K100/E15.
- the third dosage unit also can be used to deliver one or more other water-soluble nutrients, particularly other B-vitamins and vitamin C, advantageously at or above or at multiple levels of their DVs (Daily Values) where applicable.
- the dosage unit thus advantageously will include 30 mg to 1000 mg of vitamin C, 1 mg to 40 mg of vitamin B1, 1 mg to 40 mg of vitamin B2, 10 mg to 300 mg of niacin, 10 mg to 300 mg of vitamin B5, and 1 mg to 40 mg of vitamin B6.
- a particularly useful formulation includes from 30 mg to 750 mg of vitamin C, from 25 mg to 400 mg of calcium, from 1 mg to 40 mg of vitamin B1, from 1 mg to 40 mg of vitamin B2, from 10 mg to 300 mg of vitamin B5, from 1 mg to 40 mg of vitamin B6, from 6 mcg to 500 mcg of vitamin B12, from 1 mg to 100 mg of bioflavonoid complex, and from 5 mg to 300 mg of quercetin.
- the third dosage unit is designed to slowly, in a generally linear fashion, release the one or more of such water-soluble nutrients.
- the release of the water-soluble nutrients in general should occur in the stomach and small intestine (duodenum, jejunum and ileum).
- the third dosage unit when a supplement is taken with a meal, as commonly recommended, it takes about 6-12 hours to pass through stomach and small intestine. Therefore release of the water-soluble vitamins from the third dosage unit should extend for at least three hours after ingestion, and advantageously for up to a full twelve hours after ingestion.
- the third dosage unit also advantageously will be formulated to release vitamin B12 such that plasma levels of the vitamin B12 are sustained for a period of at least 6 hours, with best results achieved when formulated such that plasma levels of the vitamin B12 are sustained during the period of from 30 minutes to 24 hours after ingestion.
- Tablet contents were mixed, and tablets were formed from the resulting mixture.
- Coating ingredients were mixed, and the resulting mixture was used to coat the tablets.
- the fourth dosage unit contains nutrients and/or other supplement ingredients, such as probiotics, that are adversely affected by exposure to stomach acid or stomach digestion and that should be delivered into the lower parts of the small intestine for full activity in the large intestine.
- nutrients and/or other supplement ingredients such as probiotics
- This dosage unit is formulated to protect the probiotic microorganisms from potentially lethal acid exposure during passage through the stomach. This can be accomplished using coated or enteric-coated tablets or capsules and other solid dosage delivery forms, where the coating is designed to deliver the ingredients into the lower intestinal tract (ileum and colon).
- the fourth dosage unit is in the form of layered capsule as described in U.S. Pat. No. 5,478,570.
- Particularly useful is a triple layer, enteric release encapsulation which protects live probiotic organisms from the acidic gastric environment and releases the organisms in the intestinal tract where they can flourish and provide their health benefits.
- the inner layer or core contains the probiotic organisms (preferably Lactobacillus acidophilus and Bifidobacterium longum ) suspended in vegetable oil.
- the middle layer composed of hardened vegetable oil, surrounds and protects the inner layer.
- the outer layer or primary protective shell is composed of gelatin, pectin and glycerine and provides stability from heat, freezing and acid.
- the capsule has an outer shell that does not dissolve under pH 4 (at 37° C.) and thus is adapted to pass through the stomach intact. Once the capsule reaches the higher pH environment in the intestines, the outer gelatin shell begins to slowly dissolve, gradually exposing the inner lipid layers. The probiotics are then gradually released by the further action of lipolytic enzymes and the motion of the intestinal tract.
- the fourth dosage unit optimally is formulated to include:
- each capsule contained the Lactobacillus acidophilus and Buifodobacterium longum.
- the core was covered by a layer of the vegetable oil to protect the beneficial bacteria during passage through the stomach.
- the gelatin was provided as an outer shell over the vegetable oil to provide further protection from the acidic stomach environment.
- the forth dosage unit can be formed using a sodium alginate-ethylcellulose enteric coating system for soft gelatin capsules.
- the composition of enteric film basically consists of sodium alginate and ethylcellulose.
- the sodium alginate is insoluble in acids where the pH of the resulting solution (coating solution) falls below 3.0.
- the ethylcellulose is insoluble in water, but it is a very good film forming and adhesive polymer while the sodium alginate is a crystalline powder which does not have filming capability.
- An ethylcellulose coating solution can be formed by processing ethylcellulose in an alkaline aqueous solution (ammonia solution) to form a latex solution, for example, Surelease® coating, by Colorcon, West Point, Pa., USA.
- a latex solution for example, Surelease® coating, by Colorcon, West Point, Pa., USA.
- Small ethylcellulose particles (latex) are able to disperse uniformly in a solution for coating applications.
- the ammonia and water are evaporated and the ethylcellulose latexes are left on the tablet surface. Under heated condition, the latexes then can be annealed together to form a non-water soluble film on the tablet surface.
- Small molecular sodium alginate can be provided in the ethylcellulose aqueous solution.
- the sodium alginate will dissolve in the latex alkaline solution to form an enteric coating solution. Once the enteric coating solution is sprayed on the tablets (2-4 percent solid gain), the ammonia and water are evaporated. Ethylcellulose latexes then can be annealed to form a film.
- the sodium alginate and ethylcellulose sodium alginate-ethylcellulose solid solution
- the enteric coated tablets will stay intact in the acid condition (pH 2.6) for 6-12 hours. Both sodium alginate and ethylcellulose do not dissolve and will prevent water from penetrating into the core tablet to avoid premature release of the active ingredient. Once the tablets reach the intestine, the film starts to dissolve and the content of tablets are released instantly.
- the ratio of sodium alginate and ethylcellulose can be varied to control the release pattern and insure an instant, full release in the target physiological site for the best bioavailability.
- a preferred nutritional supplement system includes vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin C, vitamin D3, vitamin E, vitamin B5, vitamin B6, vitamin B12, vitamin B, vitamin K, lutein, lycopene, omega-3 fatty acids (from fish oil), gamma-tocopherol, silicon, beeswax, calcium, niacin, bioflavonoid complex, quercetin, phosphorus, magnesium, zinc, manganese, boron, copper, beta carotene, trace mineral protein hydrolysate for chromium, molybdenum, nickel, tin, vanadium, boron and selenium, N-acetyl cysteine, spirulena, folate, biotin, iodine, probiotic Acidopholis, and probiotic Bifidus.
- quercetin from 0 mg to 300 mg of quercetin
- the supplement system is additionally comprised of from 5 mg to 30 mg of iron.
- the supplement system is additionally comprised of 100 mcg to 1000 mcg of additional folic acid.
- a nutritional supplement delivery system particularly well adapted for the delivery of nutrients, consists of the first, second, and third dosage units.
- a nutritional supplement system, particularly well adapted for the delivery of water-soluble nutrients, consists of the first and third dosage units.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Physiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Surgical Instruments (AREA)
Abstract
A multi-part nutritional supplement system supplies nutrients to a user at advantageous locations in the digestive tract. One type of dosage unit is formulated to release vitamin B12 in the stomach and intestines of the upper GI tract, advantageously in an amount that is greater than or at multiple levels of the DV (Daily Value) of vitamin B12.
Description
- This is a continuation of International Application No. PCT/US2008/009399, filed Aug. 4, 2008, which claims the benefit of U.S. Provisional Application No. 60/953,934 filed Aug. 3, 2007 and U.S. Provisional Application No. 60/953,944 filed Aug. 3, 2007. This is a continuation-in-part of International Application No. PCT/US2008/009402, filed Aug. 4, 2008, which claims the benefit of U.S. Provisional Application No. 60/953,934 filed Aug. 3, 2007 and U.S. Provisional Application No. 60/953,944 filed Aug. 3, 2007. All the above-referenced applications are incorporated herein by reference.
- Described herein is a nutritional supplement system for the delivery of vitamins, minerals, and/or probiotics for sustaining the health of human subjects.
- Vitamin and mineral preparations are commonly administered as general nutritional supplements. Micronutrients are elements or compounds which are present in foods and herbs in small or trace amounts. These include vitamins, minerals, or other elements, and substances found in foods. The macronutrients consist of carbohydrates, fats, and proteins, which supply nutrients and calories. Some elements such as calcium, sodium, potassium, chloride, and phosphorus are consumed in relatively large amounts, while many such as iron, iodine, and zinc are consumed in small amounts. Vitamins, such as vitamin B12 and folic acid, and the minerals copper, selenium, and chromium are consumed in very small or trace amounts.
- Inasmuch as the human body does not synthesize many compounds which are essential to the human body, certain vitamins, minerals, and other nutrients can be obtained from only two sources, food and supplements. The primary source of all nutrients is food. However, many people do not acquire optimal amounts of the essential compounds and elements from the foods they eat. Thus, nutritional supplementation has become a recognized method of preserving good health.
- The consumption of probiotic supplements also can be beneficial to the well being of humans. It has been recognized that temporary or chronic digestive symptoms can be caused by a damaged or disordered intestinal flora. Consumption of a nutritional supplement preparation containing suitable microorganisms is often sufficient to alleviate or to eliminate the symptoms caused by a disordered or damaged intestinal flora.
- As used herein, “probiotics” refers to live micro-organisms, delivered in food supplements, which beneficially affect the host animal by improving its intestinal microbial balance. Antibiotics and other related compounds are not included in this definition. (J. Nutr. 1995; 125:1401-12). For humans, lactobacilli are commonly provided as probiotics, either as single species or in mixed culture with other bacteria. Other genera that have been used are bifidobacteria and streptococci. “Prebiotics” refers to non-digestible food ingredients that beneficially affect the host by selectively stimulating the growth and/or activity of bacteria in the colon.
- It has been a problem with many prior nutritional supplement systems that they provide incomplete nutrition or that a multiplicity of doses of nutrients must be taken at multiple different times to achieve a well balanced and appropriately timed delivery of nutrients to a user. Prior nutritional supplement systems have in some cases delivered nutrients to a location in the digestive tract where, although effective for uptake of the nutrients, have caused user discomfort. In other cases, one or more nutrients are released in a location that is not optimal for uptake by the body. When nutrients or probiotics are released in locations that are unfavorable reduce biological activity can result. For example, probiotics typically do not survive exposure to stomach acid.
- It has been a specific problem in the formulation of supplements for the delivery of vitamin B12 that the absorption of vitamin B12 has been found to require secretion of a glycoprotein, known as “intrinsic factor,” from cells lining the stomach. Normally, vitamin B12 is readily absorbed in the last part of the small intestine (ileum), which leads to the large intestine. However, to be absorbed, the vitamin must combine with intrinsic factor. As a result of passage through the stomach, vitamin B12 is attaches to intrinsic factor for transfer. This combination of the vitamin and intrinsic factor can then be “caught” by the ileal receptor. Without intrinsic factor, significant amounts of vitamin B12 can remain in the intestine and are excreted in the stool. Previously it has been thought that, to maximize the absorption of vitamin B12, a supplement should be formulated to deliver vitamin B12 in the stomach to maximize binding to intrinsic factor and optimize uptake of the intrinsic factor/B12 complex. But there are difficulties with supplements that provide for rapid release vitamin B12 in the stomach.
- There thus is a continuing need for user friendly systems for effectively delivering beneficial substances to the body.
- In answer to that need a nutritional supplement system is provided that supplies nutrients and/or probiotics at various appropriate locations in the digestive tract.
- One particular element of such a system is a dosage unit formulated to release vitamin B12 over time in both the stomach and the intestines of the upper GI tract.
- A multi-component oral nutritional supplement system supplies a combination of nutrients and/or probiotics at optimal locations throughout the digestive tract of a human subject for efficient nutrient utilization and user comfort and convenience.
- An optimal system includes four dosage units, although certain other beneficial systems may include two or three dosage units.
- A first dosage unit that is formulated to quickly release one or more nutrients in the stomach of a human subject. This dosage unit advantageously includes vitamins and minerals or other dietary supplement ingredients that benefit from release in the stomach and exposure to stomach acid, or are not adversely affected by such release or exposure, and/or properly are dispersed in the stomach for optimal absorption further down in the GI tract. This dosage unit advantageously is in the form of a tablet or caplet formed by compression. The tablet may be coated with a layer containing one or more nutrients that best are delivered in the stomach particularly rapidly. In general, the first dosage unit should not contain substances that are not well tolerated by the stomach or that would be harmed by the acidic environment of the stomach; such substances should be delivered in one of the other dosage units described herein.
- A second dosage unit is formulated to contain nutrients that do not require release in the stomach and exposure to stomach acid for efficient digestion and absorption, and which may cause tolerance problems (repeating, stomach upset, nausea) or loss in biological activity when released in the stomach. This dosage unit advantageously is used to deliver certain nutritional oils, notably fish oil constituents, other omega-3 fatty acid containing oils, and may also include fat-soluble micronutrients that do not require stomach digestion, such as vitamins A, D, E, and carotenoids. The dosage unit advantageously is a sealed gelatin encapsulation that can pass through the stomach before releasing the encapsulated nutrients.
- A third dosage unit is formulated to contain water-soluble nutrients and other nutrients that are typically very rapidly absorbed and therefore best delivered by sustained release so as to maintain an elevated concentration in the body over time. This dosage unit is designed to slowly, in generally linear fashion, release one or more water-soluble nutrients. The release of these nutrients is initially in the stomach and continues into the intestines of the upper GI tract. This dosage unit advantageously is formulated to release vitamin B12. The dosage unit also is useful to deliver other B-vitamins and vitamin C.
- A fourth dosage unit contains nutrients and/or other supplement ingredients such as probiotics that are adversely affected by exposure to stomach acid or stomach digestion, and that should be delivered into the lower parts of the small intestine for full activity in the large intestine. This dosage unit is formulated to protect the probiotic microorganisms from potentially lethal acid exposure during passage of the dosage unit through the stomach. Advantageously it is in the form of a three-layer capsule.
- These four dosage units are formulated for administration one time each day, and can be taken substantially simultaneously, to provide complete and appropriately timed delivery of a full range of nutrients and probiotics.
- All the dosage units of complete daily dose of the nutritional supplement system advantageously are packaged together as a multi-element package so that a user will not need to remember to combine various individual dosage units to make a complete daily dose. In some cases, to avoid the use of uncomfortably large tablets, caplets, or capsules, certain of the dosage units can be split into two or more tablets, caplets, or capsules. Because a balanced supplement system requires relatively large amount of the nutrients of the first and second dosage units, in a particularly advantageous arrangement the first dosage unit is in the form of two separate dosage elements, preferably tablets or caplets, and the second dosage unit is in the form of two separate dosage elements, preferably gel encapsulations. With that arrangement, the two first dosage unit elements, the two second dosage unit elements, one third dosage unit element, and one fourth dosage unit element can be provided together, for example in a single blister pack card or strip, so that a user will immediately know that the six elements together are a day's dose. A typical blister pack arrangement will have six attached blister strips, separated by perforated detachment lines, with each strip holding the six dosage elements that together comprise a day's dose.
- The dosage units advantageously employ various forms of extended release excipients or coatings along with immediate release excipients or coatings to deliver the various vitamins and mineral supplements over various optimum rates of release. For example, a folic acid micro-coating can be employed to release folic acid from the multi-vitamin and mineral supplement within minutes after entry into the stomach. Gel diffusion technology can be used to maximize the intestinal adsorption of vitamins B and C for over twelve hours. Providing fish oil in delayed release capsules results in rapid release in the intestines of upper GI tract, which gives maximum bioavailability and minimum stomach discomfort. And a triple layer encapsulation system provides for targeted release of probiotics to the lower GI tract.
- In general, those of ordinary skill know how to formulate dosage units with various different release profiles. Nutritional supplement dosage units may employ one or more forms of release, including, without limitation, immediate release, extended release, pulse release, variable release, controlled release, timed release, sustained release, delayed release, long acting, and combinations thereon. The various types of release can be accomplished using well known procedures and techniques.
- The time release characteristics for the release of the components may be varied by modifying the composition of layers, including modifying any of the excipients or coatings which may be present. For example, changing the composition or amount of the covering or coating layers may be used to control the release of the components. Similarly, when modified release is facilitated by the inclusion of a specific matrix material, controlling the choice and amount of modified release matrix material utilized may be used to control the release of the active components. The matrix material may be present, either surrounding individual components of the composition or over a layer of the composition, in any amount that is sufficient to yield the desired time release or time lag between release of the components.
- Various coating materials that modify the release of the components in the desired manner may be used. In particular, coating materials suitable for use in the practice include, but are not limited to polymer coating materials, hydrogels and gel-forming materials and hydrophilic polymers. Preferred polymer coating materials are cellulose acetate phthalate, cellulose acetate trimaletate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, amino methacrylate copolymers such as Eudragit® RS and RL, polyacrylic acid and polyacrylate and methacrylate copolymers such as Eudragit® S and L, polyvinyl acetaldiethylamino acetate, hydroxypropyl methylcellulose acetate succinate, and shellac.
- Preferred hydrogels and gel-forming materials include carboxyvinyl polymers, sodium alginate, sodium carmellose, calcium carmellose, sodium carboxymethyl starch, polyvinyl alcohol, hydroxyethyl cellulose, methyl cellulose, gelatin, starch, and cellulose based cross-linked polymers in which the degree of crosslinking is low so as to facilitate adsorption of water and expansion of the polymer matrix, hydroxypropyl cellulose, hydroxypropyl methylcellulose, crosslinked starch, microcrystalline cellulose, chitin, aminoacryl-methacrylate copolymer (Eudragit® RS-PM), pullulan, collagen, casein, agar, gum arabic, sodium carboxymethyl cellulose, (swellable hydrophilic polymers) poly(hydroxyalkyl methacrylate) (molecular weight about 5 k-5,000 k), polyvinylpyrrolidone (molecular weight about 10 k-360 k), anionic and cationic hydrogels, polyvinyl alcohol having a low acetate residual, a swellable mixture of agar and carboxymethyl cellulose, copolymers of maleic anhydride and styrene, ethylene, propylene or isobutylene pectin (molecular weight about 30 k-300 k), polysaccharides such as agar, acacia, karaya, tragacanth, algins and guar, polyacrylamides, Polyox® polyethylene oxides (molecular weight about 100 k-5,000 k), AquaKeep® acrylate polymers, diesters of polyglucan, crosslinked polyvinyl alcohol and poly N-vinyl-2-pyrrolidone, and sodium starch glycolate (e.g., Explotab®).
- Preferred hydrophilic polymers include polysaccharides, methyl cellulose, sodium or calcium carboxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, nitrocellulose, carboxymethyl cellulose, cellulose ethers, polyethylene oxides (e.g. Polyox®, Union Carbide), methylethyl cellulose, ethylhydroxy ethylcellulose, cellulose acetate, cellulose butyrate, cellulose propionate, gelatin, collagen, starch, maltodextrin, pullulan, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, glycerol fatty acid esters, polyacrylamide, polyacrylic acid, copolymers of methacrylic acid or methacrylic acid (e.g., Eudragit®), other acrylic acid derivatives, sorbitan esters, natural gums, lecithins, pectin, alginates, ammonia alginate, sodium, calcium, potassium alginates, propylene glycol alginate, agar, and gums such as arabic, karaya, locust bean, tragacanth, carrageens, guar, xanthan, scleroglucan and mixtures and blends thereof.
- Excipients such as plasticisers, lubricants, solvents and the like may be added to a coating. Suitable plasticisers include for example hydroxylated soy lecithin, acetylated monoglycerides, butyl phthalyl butyl glycolate, dibutyl tartrate, diethyl phthalate, dimethyl phthalate, ethyl phthalyl ethyl glycolate, glycerin, propylene glycol, triacetin, citrate, tripropioin, diacetin, dibutyl phthalate, acetyl monoglyceride, polyethylene glycols, castor oil, triethyl citrate, polyhydric alcohols, glycerol, acetate esters, glycerol triacetate, acetyl triethyl citrate, dibenzyl phthalate, dihexyl phthalate, butyl octyl phthalate, diisononyl phthalate, butyl octyl phthalate, dioctyl azelate, epoxidized tallate, triisoctyl trimellitate, diethylhexyl phthalate, di-n-octyl phthalate, di-i-octyl phthalate, di-i-decyl phthalate, di-n-undecyl phthalate, di-n-tridecyl phthalate, tri-2-ethylhexyl trimellitate, di-2-ethylhexyl adipate, di-2-ethylhexyl sebacate, di-2-ethylhexyl azelate, dibutyl sebacate.
- A coating layer may be any suitable modified release matrix material or suitable combination of modified release matrix materials. Such materials are known to those skilled in the art. Modified release matrix materials suitable for the practice of the present invention include, but are not limited to, microcrystalline cellulose, sodium carboxymethylcellulose, hydroxyalkylcelluloses (e.g., hydroxypropylmethylcellulose and hydroxypropylcellulose), polyethylene oxide, alkylcelluloses (e.g., methylcellulose and ethylcellulose), polyethylene glycol, polyvinylpyrrolidone, cellulose acetate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose acetate trimellitate, polyvinylacetate phthalate, polyalkylmethacrylates, polyvinyl acetate and mixtures thereof.
- The dissolution characteristics of a dosage form can be manipulated not only through the quantity of the excipients in the finished dosage form and size of the finished dosage form, but also by a judicious selection and blending of various molecular weights of a given polymer or polymers, as is known to those skilled in the art.
- Film coated tablets may be prepared by coating tablets using techniques such as rotating pan coating methods or air suspension methods to deposit a contiguous film layer on a tablet. This procedure is often done to improve the aesthetic appearance of tablets, but may also be done to improve the swallowing of tablets, to mask an obnoxious odor or taste, or to improve to usual properties of an unsightly uncoated tablet. Compressed tablets, for example, without limitation, may be prepared by mixing the components with excipients intended to add binding or disintegration qualities. The mixture is either directly compressed, or granulated then compressed, using methods and machinery quite well known to those in the industry.
- One or more of the dosage units of the nutritional supplement system described herein can also be used to deliver prebiotics. Example prebiotics include oligosaccharides such as glucose, fructose, xylose, galactose, lactose, mannose, arabinose, D-fucose, L-fucose, rhamnose, Actilight, Biotose, Palatinose, IMO, cellobiose, gentiobiose, laevan, maltodextrin, maltose, melibiose, raffinose, lactose, panorich, melezitose, raftiline, raftilose, stachyose, sucrose, tagatose, xylan, fructooligosaccharide (FOS), galactooligosaccharide (GOS), soy oligosaccharide, lactosucrose, maltooligosaccharide, xylooligosaccharide, inulin and fractionated inulin as well as one or more dietary fiber components such as coconut (including coconut endosperm fibber), beet pulp (such as sugarbeet pulp), chicory (including chicory pulp), oat bran concentrate, rice bran, carob bean, gum talhar and guar gum.
- The nutritional supplement system will be better understood with reference to the following specific discussion and examples which detail certain procedures for the preparation of the dosage units. All references made to specific examples are for the purposes of illustration. They are not to be considered limiting as to the scope and nature of the present invention.
- The first dosage unit is formulated to contain vitamins and minerals, typically at or near their USFDA Daily Value (DV) level, that best are delivered in the stomach. Such nutrients include vitamins, minerals and other dietary supplement ingredients that benefit from release in the stomach and exposure to stomach acid, or that are not adversely affected by such release or exposure, and/or that properly are dispersed in the stomach for optimal absorption further down the GI tract.
- This dosage unit advantageously is in the form of a tablet or caplet formed by compression of a blend containing vitamins, minerals and appropriate excipients. Because rapid delivery of nutrients is desired, the first dosage unit should be formulated for release in less than one hour, and best within 0.75 hour.
- The tablet or caplet may be coated with a layer containing one or more nutrients that best are delivered particularly rapidly. Advantageously, the coating will include folic acid (folate) for rapid release. As described in U.S. Pat. Nos. 6,852,335 and 6,465,013, folic acid in an outer coating is released more rapidly than when folic acid is contained in the core of a tablet, resulting in increased bioavailability.
- The first dosage unit optimally is formulated to include:
-
- from 0 mg to 600 mg of phosphorus,
- from 50 mg to 600 mg of magnesium,
- from 30 mg to 500 mg of vitamin C,
- from 1 mg to 30 mg of zinc,
- from 30 IU to 400 IU of vitamin E,
- from 0 mg to 5 mg of manganese,
- from 5 mg to 50 mg of vitamin B3,
- from 0 mg to 5 mg of boron,
- from 0.5 mg to 5 mg of copper,
- from 0 IU to 10,000 IU of vitamin A,
- from 0 mg to 6 mg of beta carotene,
- from 1 mg to 30 mg of pantothenic acid,
- from 0 mg to 200 mcg of trace mineral protein hydrolysate for chromium, molybdenum, nickel, tin, vanadium, and selenium,
- from 0 mcg to 200 mcg of vitamin K,
- from 0 mg to 100 mg of N-acetyl cysteine,
- from 0 mg to 25 mg of silicon,
- from 1 mg to 10 mg of vitamin B6,
- from 1 mg to 10 mg of vitamin B1,
- from 1 mg to 10 mg of vitamin B2,
- from 3 mcg to 25 mcg of vitamin B12,
- from 200 IU to 800 IU of vitamin D3,
- from 100 mcg to 800 mcg of folate,
- from 50 mcg to 600 mcg of biotin, and
- from 50 mcg to 500 mcg of iodine.
- Example formulations of a first nutritional supplement dosage unit, in the form of immediate release tablets, are shown in the following table:
-
Men's Women's Senior's Vitamin/ Vitamin/ Vitamin/ Mineral Mineral Mineral Tablet Tablet Tablet Label Claim Label Claim Label Claim Ingredient (per dose) (per dose) (per dose) Dicalcium phosphate (Ca) 450 mg 450 mg 450 mg Dicalcium phosphate (P) 350 mg 350 mg 350 mg Magnesium oxide 200 mg 200 mg 200 mg Microcrystalline cellulose n/a n/a n/a Ascorbic acid 120 mg 120 mg 120 mg Zinc gluconate 15 mg 15 mg 22.5 mg Ferrous fumarate 18 mg n/a n/a Hydroxypropyl n/a n/a n/a methylcellulose Vitamin E succinate 60 IU 60 IU 60 IU Manganese gluconate 2 mg 2 mg 2 mg Croscarmellose sodium n/a n/a n/a Niacinamide 20 mg 20 mg 30 mg Boron protein hydrolysate 1 mg 1 mg 1 mg Magnesium stearate n/a n/a n/a Copper gluconate 2 mg 2 mg 2 mg Vitamin A acetate 2500 IU 2500 IU 1500 IU Beta carotene 2500 IU 2500 IU 1500 IU d-Calcium pantothenate 10 mg 10 mg 15 mg Sea kelp powder n/a n/a n/a Selenium* 70 mcg 70 mcg 70 mcg Chromium* 120 mcg 120 mcg 120 mcg Molybdenum* 75 mcg 75 mcg 75 mcg Nickel* 15 mcg 15 mcg 5 mcg Tin* 10 mcg 10 mcg 10 mcg Vanadium* 20 mcg 20 mcg 20 mcg Vitamin K 80 mcg 80 mcg 80 mcg N-acetyl cysteine n/a n/a 25 mg Spirulina n/a n/a n/a Inositol n/a n/a n/a Choline bitartrate n/a n/a n/a Alfalfa powder n/a n/a n/a Grapefruit bioflavonoid n/a n/a n/a Hesperidin complex n/a n/a n/a Lemon bioflavonoid n/a n/a n/a Mixed tocopherols n/a n/a n/a Orange bioflavonoid n/a n/a n/a Rice bran powder n/a n/a n/a Rose hips powder n/a n/a n/a Acerola extract n/a n/a n/a Silicon dioxide 2 mg 2 mg 2 mg Pyridoxine hydrochloride 2 mg 2 mg 4 mg Thiamine mononitrate 1.5 mg 1.5 mg 2.25 mg Riboflavin (nutrient) 1.7 mg 1.7 mg 2.55 mg Riboflavin (color) n/a n/a n/a Hydroxylated soy lecithin n/a n/a n/a Carnauba wax n/a n/a n/a Vitamin B12 6 mcg 6 mcg 24 mcg Vitamin D3 400 IU 400 IU 800 IU Folic acid 400 mcg 400 mcg 400 mcg Biotin 300 mcg 300 mcg 300 mcg Potassium iodide (I) 150 mcg 150 mcg 150 mcg *Supplied as a trace mineral protein hydrolysate - Coated tablets were assembled by combining the ingredients to form the blend for a core and compressing the blend to form tablets. The tablets were then coated with a film coating solution. Two such tablets served as one day's dose of the first dosage unit.
- The second dosage unit is formulated to contain nutrients that do not require release in the stomach and exposure to stomach acid for efficient digestion and absorption, and which may cause tolerance problems (repeating, stomach upset, nausea) or loss in biological activity when released in the stomach. This dosage unit advantageously is used to deliver certain nutritional oils, notably fish oil constituents, other omega-3 fatty acid containing oils, and may also include fat-soluble micronutrients that do not require stomach digestion, such as vitamins A, D, E, and carotenoids.
- The dosage unit advantageously is a sealed gelatin encapsulation that can pass through the stomach before releasing the encapsulated nutrients.
- This dosage unit is formulated to pass through the stomach without releasing its contents, notably fish oil, and remain unopened until after it naturally passes into the intestines of the upper GI tract. Release in the stomach can lead to an unpleasant taste caused by repeating fish oil aroma (“fish burp”) in the mouth of a user.
- This dosage form thus advantageously is a soft capsule having a coating resistant to gastric juice to achieve a delayed release of the fish oil in the intestine, advantageously a coating of a polymer such as methacrylic acid. Delayed release can also be accomplished or enhanced by cross-linking of gelatin used to form such a capsule or by providing derivates of starch in the casing of such a capsule.
- The second dosage unit optimally is formulated to include:
-
- from 0 mg to 10 mg of lutein,
- from 0 mg to 10 mg of lycopene,
- from 50 IU to 400 IU of vitamin D3,
- from 50 IU to 400 IU of vitamin E,
- from 50 mg to 3500 mg of total omega-3 fatty acids (fish oil), and
- from 0 mg to 250 mg of gamma-tocopherol.
- An example formulation of a second nutritional supplement dosage unit, in the form of a soft gelatin capsule, is shown in the following table:
-
Enteric Coated Fat Soluble Nutrients Label Claim Ingredient (per dose) Lutein ester suspension 2 mg Lycopene suspension 2.5 mg Vitamin D3 200 IU Mixed tocotrienols & tocopherols 1 mg Vitamin E (a-tocopherol 140 IU concentrate) Total omega-3 fatty acids 500 mg Gamma tocopherol 25 mg Beta and delta tocopherol 10 mg Silicon dioxide n/a Beeswax n/a Glycerin n/a Gelatin n/a Annatto suspension (Ultrabix n/a 03190) Water n/a Enteric coating (TM29Z19241 n/a Clear) Surelease (E-7-19040) n/a Natural vanillin n/a - The nutritional ingredients were mixed to form a fill mixture. Gel mass ingredients were mixed to form a gel mass. Formed halves were injected with the fill mixture and then joined to form capsules. Coating ingredients were mixed to make a coating mixture; and then the formed capsules were coated with the mixture in a tablet coating apparatus. The finished product was then dried.
- Two of the resulting encapsulations served as one day's dose of the second dosage unit.
- The third dosage unit is formulated to contain one or more water-soluble nutrients and/or other nutrients that are typically very rapidly absorbed and therefore best delivered by sustained release so as to maintain an elevated concentration in the body over time.
- Certain rapidly-absorbed, typically water-soluble nutrients are best delivered by sustained release so as to maintain an elevated concentration in the body over time. These include B-vitamins and vitamin C. If given in an immediate release dosage unit, the concentrations of such vitamins in the body rapidly decline after an initial peak. Moreover, the absorptive sites and nutrient uptake mechanisms in the intestinal wall can be overwhelmed by the high intestinal nutrient concentrations caused by immediate release dosage units, which is known to reduce the overall amount that can be taken up by the body. Sustained release dosage units of such vitamins have been used to overcome these problems. But sustained release dosage units of such vitamins have typically excluded vitamin B12 because of the perceived need to deliver an entire dose of vitamin B12 to the stomach so that it can be combined with intrinsic factor.
- Testing now shows that vitamin B12, delivered by sustained release, can result in improved bioavailability of vitamin B12 as compared to immediate release in the stomach. In the particular tests conducted, subjects were given a tablet containing 9.8 mg vitamin B1, 11.5 mg vitamin B2, 13.1 mg vitamin B6, 90 μg vitamin B12 and 518 mg vitamin C. For the B vitamins, ingestion of a comparable immediate-release formulation produced peak plasma concentrations for B1, B2 and B6 at 2 hours post ingestion and at 3 hours for serum vitamin B12. B-vitamin concentrations then declined rapidly from peak concentrations, returning to baseline by 6 hr for B1 and B6 and by 12 hr for B2 and B12. In contrast, ingestion of the sustained release formulation resulted in delayed peak serum and plasma concentrations until 4 hr for B1 and B2 and 5 hr for B6 and B12. Sustained-release tablet delivery was found to improve the bioavailability of vitamin C and at least three B-vitamins, including vitamin B12, in comparison to immediate release delivery.
- The third dosage unit thus is formulated to release vitamin B12 in the stomach and intestines of the upper GI tract, advantageously in an amount that is greater than or at multiple levels of the DV (Daily Value) of vitamin B12. This is accomplished by including vitamin B12 in an amount of from 3 mcg to 500 mcg, with best results at a vitamin B12 amount of from 6 mcg to 500 mcg.
- Best results for the delivery of vitamin B12 are achieved with a dosage unit that releases vitamin B12, as determined by USP dissolution apparatus at 37° C. at 50 RPM paddle speed in 900 ml of 0.1N HCl, continuously and generally linearly over a period of 6 hours. It is particularly advantageous for the dosage unit to be formulated to allow at least 15% of the vitamin B12 to dissolve in one hour in 900 ml of 0.1N HCl at 37° C. This dosage form, after ingestion by a subject, will sustain plasma levels of the vitamin B12 for a period 12 hours. Good delivery of vitamin B12 is achieved, for example, with third dosage unit tablet of 350 mg to 1500 mg total weight, where the tablet contains 20 mcg to 100 mcg of vitamin B12 and contains 5% to 20% HPMC K100/E15 by weight. Superior results are achieved with tablets having 9.5% to 14% HPMC K100/E15.
- The third dosage unit also can be used to deliver one or more other water-soluble nutrients, particularly other B-vitamins and vitamin C, advantageously at or above or at multiple levels of their DVs (Daily Values) where applicable. The dosage unit thus advantageously will include 30 mg to 1000 mg of vitamin C, 1 mg to 40 mg of vitamin B1, 1 mg to 40 mg of vitamin B2, 10 mg to 300 mg of niacin, 10 mg to 300 mg of vitamin B5, and 1 mg to 40 mg of vitamin B6. A particularly useful formulation includes from 30 mg to 750 mg of vitamin C, from 25 mg to 400 mg of calcium, from 1 mg to 40 mg of vitamin B1, from 1 mg to 40 mg of vitamin B2, from 10 mg to 300 mg of vitamin B5, from 1 mg to 40 mg of vitamin B6, from 6 mcg to 500 mcg of vitamin B12, from 1 mg to 100 mg of bioflavonoid complex, and from 5 mg to 300 mg of quercetin.
- The third dosage unit is designed to slowly, in a generally linear fashion, release the one or more of such water-soluble nutrients. The release of the water-soluble nutrients in general should occur in the stomach and small intestine (duodenum, jejunum and ileum).
- Generally, when a supplement is taken with a meal, as commonly recommended, it takes about 6-12 hours to pass through stomach and small intestine. Therefore release of the water-soluble vitamins from the third dosage unit should extend for at least three hours after ingestion, and advantageously for up to a full twelve hours after ingestion. The third dosage unit also advantageously will be formulated to release vitamin B12 such that plasma levels of the vitamin B12 are sustained for a period of at least 6 hours, with best results achieved when formulated such that plasma levels of the vitamin B12 are sustained during the period of from 30 minutes to 24 hours after ingestion.
- An example formulation of a third nutritional supplement dosage unit, in the form of a sustained release tablet, is shown in the following table:
-
Sustained Release Vitamin B + C Tablet Label Claim Ingredient (per dose) Calcium ascorbate (Ca) 43 mg Calcium ascorbate (Vitamin C) 380 mg Calcium carbonate (Ca) 7 mg Thiamin mononitrate 7.5 mg Riboflavin 8.5 mg Niacinamide 100 mg Calcium pantothenate 50 mg Pyridoxine hydrochloride 10 mg Vitamin B12 30 mcg Citrus bioflavonoids 25 mg Quercetin 50 mg Microcrystalline cellulose n/a Magnesium stearate n/a Silicon dioxide n/a Hydroxypropyl methylcellulose n/a Hydroxylated soy lecithin n/a - Tablet contents were mixed, and tablets were formed from the resulting mixture. Coating ingredients were mixed, and the resulting mixture was used to coat the tablets.
- The fourth dosage unit contains nutrients and/or other supplement ingredients, such as probiotics, that are adversely affected by exposure to stomach acid or stomach digestion and that should be delivered into the lower parts of the small intestine for full activity in the large intestine.
- This dosage unit is formulated to protect the probiotic microorganisms from potentially lethal acid exposure during passage through the stomach. This can be accomplished using coated or enteric-coated tablets or capsules and other solid dosage delivery forms, where the coating is designed to deliver the ingredients into the lower intestinal tract (ileum and colon).
- In one arrangement the fourth dosage unit is in the form of layered capsule as described in U.S. Pat. No. 5,478,570.
- Particularly useful is a triple layer, enteric release encapsulation which protects live probiotic organisms from the acidic gastric environment and releases the organisms in the intestinal tract where they can flourish and provide their health benefits.
- For the triple layer delivery system, the inner layer or core contains the probiotic organisms (preferably Lactobacillus acidophilus and Bifidobacterium longum) suspended in vegetable oil. The middle layer, composed of hardened vegetable oil, surrounds and protects the inner layer. The outer layer or primary protective shell is composed of gelatin, pectin and glycerine and provides stability from heat, freezing and acid.
- The capsule has an outer shell that does not dissolve under pH 4 (at 37° C.) and thus is adapted to pass through the stomach intact. Once the capsule reaches the higher pH environment in the intestines, the outer gelatin shell begins to slowly dissolve, gradually exposing the inner lipid layers. The probiotics are then gradually released by the further action of lipolytic enzymes and the motion of the intestinal tract.
- The fourth dosage unit optimally is formulated to include:
-
- from 250,000 cfu to 20 billion cfu of Lactobacillus acidophilus,
- and from 250,000 cfu to 20 billion cfu of Buifodobacterium longum.
- An example formulation of a fourth nutritional supplement dosage unit, in the form of a delayed release capsule, is shown in the following table:
-
Triple-Layer Probiotic Capsule Label Claim Ingredient (per dose) Lactobacillus acidophilus 250M CFU Bifidobacterium longum 250M CFU Coconut/palm oil n/a Gelatin n/a Glycerin n/a Soy lecithin n/a Pectin n/a - The ingredients were combined in layered capsules. A core of each capsule contained the Lactobacillus acidophilus and Buifodobacterium longum.
- The core was covered by a layer of the vegetable oil to protect the beneficial bacteria during passage through the stomach. The gelatin was provided as an outer shell over the vegetable oil to provide further protection from the acidic stomach environment.
- In a second example arrangement, the forth dosage unit can be formed using a sodium alginate-ethylcellulose enteric coating system for soft gelatin capsules.
- In this arrangement, the composition of enteric film basically consists of sodium alginate and ethylcellulose. The sodium alginate is insoluble in acids where the pH of the resulting solution (coating solution) falls below 3.0. The ethylcellulose is insoluble in water, but it is a very good film forming and adhesive polymer while the sodium alginate is a crystalline powder which does not have filming capability.
- An ethylcellulose coating solution can be formed by processing ethylcellulose in an alkaline aqueous solution (ammonia solution) to form a latex solution, for example, Surelease® coating, by Colorcon, West Point, Pa., USA. Small ethylcellulose particles (latex) are able to disperse uniformly in a solution for coating applications. By spraying the ethylcellulose latex aqueous solution on tablets in a coating system upon heating, the ammonia and water are evaporated and the ethylcellulose latexes are left on the tablet surface. Under heated condition, the latexes then can be annealed together to form a non-water soluble film on the tablet surface.
- Small molecular sodium alginate can be provided in the ethylcellulose aqueous solution. The sodium alginate will dissolve in the latex alkaline solution to form an enteric coating solution. Once the enteric coating solution is sprayed on the tablets (2-4 percent solid gain), the ammonia and water are evaporated. Ethylcellulose latexes then can be annealed to form a film. The sodium alginate and ethylcellulose (sodium alginate-ethylcellulose solid solution) is molecularly mixed and uniformly coated on the tablet surface.
- Once the enteric coated tablets are administered and reach stomach, the enteric coated tablets will stay intact in the acid condition (pH 2.6) for 6-12 hours. Both sodium alginate and ethylcellulose do not dissolve and will prevent water from penetrating into the core tablet to avoid premature release of the active ingredient. Once the tablets reach the intestine, the film starts to dissolve and the content of tablets are released instantly. The ratio of sodium alginate and ethylcellulose can be varied to control the release pattern and insure an instant, full release in the target physiological site for the best bioavailability.
- In its entirety, a preferred nutritional supplement system includes vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin C, vitamin D3, vitamin E, vitamin B5, vitamin B6, vitamin B12, vitamin B, vitamin K, lutein, lycopene, omega-3 fatty acids (from fish oil), gamma-tocopherol, silicon, beeswax, calcium, niacin, bioflavonoid complex, quercetin, phosphorus, magnesium, zinc, manganese, boron, copper, beta carotene, trace mineral protein hydrolysate for chromium, molybdenum, nickel, tin, vanadium, boron and selenium, N-acetyl cysteine, spirulena, folate, biotin, iodine, probiotic Acidopholis, and probiotic Bifidus.
- A particularly complete and advantageous system comprises
- from 0 mg to 10 mg of lutein,
- from 0 mg to 10 mg of lycopene,
- from 200 IU to 2000 IU of vitamin D3,
- from 80 IU to 450 IU of vitamin E,
- from 50 mg to 3500 mg of total omega-3 fatty acids (fish oil),
- from 0 mg to 250 mg of gamma-tocopherol,
- from 0 mg to 25 mg of silicon,
- from 30 mg to 1000 mg of vitamin C,
- from 25 mg to 1200 mg of elemental calcium, dosed in the form of a pharmaceutically acceptable calcium compound,
- from 1 mg to 41 mg of vitamin B 1,
- from 1 mg to 41 mg of vitamin B2,
- from 5 mg to 300 mg of niacin,
- from 10 mg to 300 mg of vitamin B5,
- from 1 mg to 40 mg of vitamin B6,
- from 3 mcg to 503 mcg of vitamin B12,
- from 0 mg to 100 mg of bioflavonoid complex,
- from 0 mg to 300 mg of quercetin,
- from 0 mg to 25 mg of silicon,
- from 0 mg to 1200 mg of phosphorus,
- from 50 mg to 600 mg of magnesium,
- from 1 mg to 30 mg of zinc,
- from 0 mg to 10 mg of manganese,
- from 0 mg to 10 mg of boron,
- from 0.5 mg to 5 mg of copper,
- from 0 IU to 10,000 IU of vitamin A,
- from 0 mg to 12 mg of beta carotene,
- from 0 mg to 200 mcg of chromium, molybdenum, nickel, tin, vanadium, and selenium,
- from 0 mcg to 200 mcg of vitamin K,
- from 0 mg to 100 mg of N-acetyl cysteine,
- from 100 mcg to 1000 mcg of folate,
- from 10 mcg to 600 mcg of biotin,
- from 50 mcg to 500 mcg of iodine,
- from 250,000 cfu to 20 billion cfu of probiotic Acidopholis, and
- from 250,000 cfu to 20 billion cfu of probiotic Bifidus.
- In one embodiment for women, the supplement system is additionally comprised of from 5 mg to 30 mg of iron.
- In one embodiment formulated for users above the age of fifty, the supplement system is additionally comprised of 100 mcg to 1000 mcg of additional folic acid.
- It will be appreciated that advantageous systems for the delivery of nutrients also can employ fewer than all four of the dosage units in some instances. A nutritional supplement delivery system, particularly well adapted for the delivery of nutrients, consists of the first, second, and third dosage units. A nutritional supplement system, particularly well adapted for the delivery of water-soluble nutrients, consists of the first and third dosage units.
- In view of the many possible embodiments to which the principles of the disclosed invention may be applied, it should be recognized that the illustrated embodiments are only preferred examples of the invention and should not be taken as limiting the scope of the invention. Rather, the scope of the invention is defined by the following claims.
Claims (83)
1. A nutritional supplement system for human subjects consisting essentially of:
a first nutritional supplement dosage unit, the first dosage unit being formulated to release one or more nutrients in the stomach of a human subject;
a second nutritional supplement dosage unit, the second dosage unit being formulated to release one or more nutrients in the upper intestinal tract of the subject, the one or more nutrients being selected from the group consisting of nutrients that do not require release in the stomach and exposure to stomach acid for efficient digestion and absorption and that cause tolerance problems or are subject to a loss in biological activity when released in the stomach;
a third nutritional supplement dosage unit, the third dosage unit being formulated to continually release one or more nutrients starting in the stomach and continuing into the upper intestinal tract of the subject, the one or more nutrients being selected from the group consisting of water-soluble nutrients and other nutrients that are typically very rapidly absorbed and are best delivered by sustained release so as to maintain an elevated concentration in the body over time; and
a fourth nutritional supplement dosage unit, the fourth dosage unit being formulated to release one or more supplement ingredients in the lower intestinal tract of the subject, the supplement ingredients being selected from the group consisting of nutrients and other supplement ingredients that are adversely affected by exposure to stomach acid or stomach digestion.
2. The system of claim 1 wherein:
the first nutritional supplement dosage unit comprises a plurality of vitamins and minerals and is formulated for immediate release in the subject's stomach;
the second nutritional supplement dosage unit comprises nutritional oils including omega-3 fatty acids;
the third nutritional supplement dosage unit comprises vitamin B12 and is formulated for sustained release of vitamin B12 starting in the stomach and continuing into the intestines of the subject; and
the fourth nutritional supplement dosage unit comprises Lactobacillus acidophilus and Buifodobacterium longum.
3. The system of claim 2 wherein the third dosage unit further comprises:
one or more additional B-vitamin(s); and
vitamin C.
4. The system of claim 1 wherein the third nutritional supplement dosage unit comprises vitamin B12 and is formulated to provide elevated plasma levels of vitamin B12 for a period of at least 12 hours after ingestion.
5. The system of claim 1 wherein the third nutritional supplement dosage unit comprises vitamin B12 and is formulated to allow at least 15% of the vitamin B12 to dissolve in one hour in 900 ml of 0.1N HCl at 37° C.
6. The system of claim 1 wherein:
the first nutritional supplement dosage unit consists of two tablets or two caplets;
the second nutritional supplement dosage unit consists of two gel encapsulations;
the third nutritional supplement dosage unit consists of one tablet or caplet; and
the fourth nutritional supplement dosage unit consists of one layered tablet.
7. The system of claim 6 wherein the six dosage unit elements of the first, second, third, and fourth dosage units are packaged in a common blister pack such that a day's complete dose is packaged together.
8. The system of claim 1 wherein:
the first nutritional supplement dosage unit comprises:
from 0 mg to 600 mg of phosphorus,
from 50 mg to 600 mg of magnesium,
from 30 mg to 500 mg of vitamin C,
from 1 mg to 30 mg of zinc,
from 30 IU to 400 IU of vitamin E,
from 0 mg to 5 mg of manganese,
from 5 mg to 50 mg of vitamin B3,
from 0 mg to 5 mg of boron,
from 0.5 mg to 5 mg of copper,
from 0 IU to 10,000 IU of vitamin A,
from 0 mg to 6 mg of beta carotene,
from 1 mg to 30 mg of pantothenic acid,
from 0 mg to 200 mcg of trace mineral protein hydrolysate for chromium, molybdenum, nickel, tin, vanadium, and selenium,
from 0 mcg to about 200 mcg of vitamin K,
from 0 mg to 100 mg of N-acetyl cysteine,
from 0 mg to 25 mg of silicon,
from 1 mg to 10 mg of vitamin B6,
from 1 mg to 10 mg of vitamin B1,
from 1 mg to 10 mg of vitamin B2,
from 3 mcg to 25 mcg of vitamin B12,
from 200 IU to 800 IU of vitamin D3,
from 100 mcg to 800 mcg of folate,
from 50 mcg to 600 mcg of biotin, and
from 50 mcg to 500 mcg of iodine;
the second nutritional supplement dosage unit comprises:
from 0 mg to 10 mg of lutein,
from 0 mg to 10 mg of lycopene,
from 50 IU to 400 IU of vitamin D3,
from 50 IU to 400 IU of vitamin E,
from 50 mg to 3500 mg of total omega-3 fatty acids (fish oil), and
from 0 mg to 250 mg of gamma-tocopherol;
the third nutritional supplement dosage unit comprises
from 30 mg to 750 mg of vitamin C,
from 25 mg to 400 mg of calcium,
from 1 mg to 40 mg of vitamin B1,
from 1 mg to 40 mg of vitamin B2,
from 10 mg to 300 mg of vitamin B5,
from 1 mg to 40 mg of vitamin B6,
from 6 mcg to 500 mcg of vitamin B12,
from 0 mg to 100 mg of bioflavonoid complex,
from 0 mg to 300 mg of quercetin; and
the fourth nutritional supplement dosage unit comprises:
from 250,000 cfu to 20 billion cfu of Lactobacillus acidophilus,
and from 250,000 cfu to 20 billion cfu of Buifodobacterium longum.
9. The system of claim 8 wherein the first nutritional supplement dosage unit further comprises from 5 mg to 30 mg of iron.
10. The system of claim 8 wherein the first nutritional supplement dosage unit further comprises from 100 mcg to 1000 mcg of folic acid.
11. A method for delivering nutrients and probiotics to a human subject, the method comprising orally administering a nutritional supplement system consisting essentially of:
a first nutritional supplement dosage unit, the first dosage unit being formulated to release one or more nutrients in the stomach of a human subject;
a second nutritional supplement dosage unit, the second dosage unit being formulated to release one or more nutrients in the upper intestinal tract of the subject, the one or more nutrients being selected from the group consisting of nutrients that do not require release in the stomach and exposure to stomach acid for efficient digestion and absorption and that cause tolerance problems or are subject to a loss in biological activity when released in the stomach;
a third nutritional supplement dosage unit, the third dosage unit being formulated to continually release one or more nutrients starting in the stomach and continuing into the upper intestinal tract of the subject, the one or more nutrients being selected from the group consisting of water-soluble nutrients and other nutrients that are typically very rapidly absorbed and are best delivered by sustained release so as to maintain an elevated concentration in the body over time; and
a fourth nutritional supplement dosage unit, the fourth dosage unit being formulated to release one or more supplement ingredients in the lower intestinal tract of the subject, the supplement ingredients being selected from the group consisting of nutrients and other supplement ingredients that are adversely affected by exposure to stomach acid or stomach digestion.
12. The method of claim 11 wherein:
the first nutritional supplement dosage unit comprises a plurality of vitamins and minerals and is formulated for immediate release in the subject's stomach;
the second nutritional supplement dosage unit comprises omega-3 fatty acids;
the third nutritional supplement dosage unit comprises vitamin B12 and is formulated for sustained release of vitamin B12 starting in the stomach and continuing into the intestines of the subject sufficient to provide elevated plasma levels of vitamin B12 for a period 12 hours after ingestion; and
the fourth nutritional supplement dosage unit comprises Lactobacillus acidophilus and Buifodobacterium longum.
13. The method of claim 12 wherein the third dosage unit further comprises:
one or more additional B-vitamin(s); and
vitamin C.
14. The method of claim 11 wherein the third nutritional supplement dosage unit comprises vitamin B12 and is formulated to provide elevated plasma levels of vitamin B12 for a period of at least 12 hours after ingestion.
15. The method of claim 11 wherein the third nutritional supplement dosage unit comprises vitamin B12 and is formulated to allow at least 15% of the vitamin B12 to dissolve in one hour in 900 ml of 0.1N HCl at 37° C.
16. The method of claim 11 wherein:
the first nutritional supplement dosage unit consists of two tablets or two caplets;
the second nutritional supplement dosage unit consists of two gel encapsulations;
the third nutritional supplement dosage unit consists of one tablet or caplet; and
the fourth nutritional supplement dosage unit consists of one layered tablet.
17. The method of claim 16 wherein the six dosage unit elements of the first, second, third, and fourth dosage units are packaged in a common blister pack such that a day's complete dose is packaged together.
18. The method of claim 11 wherein the first, second, third and fourth nutritional supplement dosage units are administered substantially simultaneously.
19. A nutritional supplement system for human subjects consisting essentially of:
a first nutritional supplement dosage unit, the first dosage unit being formulated to release one or more nutrients in the stomach of a human subject;
a second nutritional supplement dosage unit, the second dosage unit being formulated to release one or more nutrients in the upper intestinal tract of the subject, the one or more nutrients being selected from the group consisting of nutrients that do not require release in the stomach and exposure to stomach acid for efficient digestion and absorption and that cause tolerance problems or are subject to a loss in biological activity when released in the stomach; and
a third nutritional supplement dosage unit, the third dosage unit being formulated to continually release one or more nutrients starting in the stomach and continuing into the upper intestinal tract of the subject, the one or more nutrients being selected from the group consisting of water-soluble nutrients and other nutrients that are typically very rapidly absorbed and are best delivered by sustained release so as to maintain an elevated concentration in the body over time.
20. The system of claim 19 wherein:
the first nutritional supplement dosage unit comprises a plurality of vitamins and minerals and is formulated for immediate release in the subject's stomach;
the second nutritional supplement dosage unit comprises nutritional oils including omega-3 fatty acids; and
the third nutritional supplement dosage unit comprises vitamin B12 and is formulated for sustained release of vitamin B12 starting in the stomach and continuing into the intestines of the subject.
21. The system of claim 20 wherein the third dosage unit further comprises:
one or more additional B-vitamin(s); and
vitamin C.
22. The system of claim 19 wherein the third nutritional supplement dosage unit comprises vitamin B12 and is formulated to provide elevated plasma levels of vitamin B12 for a period of at least 12 hours after ingestion.
23. The system of claim 19 wherein the third nutritional supplement dosage unit comprises vitamin B12 and is formulated to allow at least 15% of the vitamin B12 to dissolve in one hour in 900 ml of 0.1N HCl at 37° C.
24. The system of claim 19 wherein:
the first nutritional supplement dosage unit consists of two tablets or two caplets;
the second nutritional supplement dosage unit consists of two gel encapsulations; and
the third nutritional supplement dosage unit consists of one tablet or caplet.
25. The system of claim 24 wherein the five dosage unit elements of the first, second, and third dosage units are packaged in a common blister pack such that a day's complete dose is packaged together.
26. A method for delivering nutrients to a human subject, the method comprising orally administering a nutritional supplement system consisting essentially of:
a first nutritional supplement dosage unit, the first dosage unit being formulated to release one or more nutrients in the stomach of a human subject;
a second nutritional supplement dosage unit, the second dosage unit being formulated to release one or more nutrients in the upper intestinal tract of the subject, the one or more nutrients being selected from the group consisting of nutrients that do not require release in the stomach and exposure to stomach acid for efficient digestion and absorption and that cause tolerance problems or are subject to a loss in biological activity when released in the stomach; and
a third nutritional supplement dosage unit, the third dosage unit being formulated to continually release one or more nutrients starting in the stomach and continuing into the upper intestinal tract of the subject, the one or more nutrients being selected from the group consisting of water-soluble nutrients and other nutrients that are typically very rapidly absorbed and are best delivered by sustained release so as to maintain an elevated concentration in the body over time.
27. The method of claim 26 wherein:
the first nutritional supplement dosage unit comprises a plurality of vitamins and minerals and is formulated for immediate release in the subject's stomach;
the second nutritional supplement dosage unit comprises omega-3 fatty acids; and
the third nutritional supplement dosage unit comprises vitamin B12 and is formulated for sustained release of vitamin B12 starting in the stomach and continuing into the intestines of the subject sufficient to provide elevated plasma levels of vitamin B12 for a period 12 hours after ingestion.
28. The method of claim 27 wherein the third dosage unit further comprises:
one or more additional B-vitamin(s); and
vitamin C.
29. The method of claim 26 wherein the third nutritional supplement dosage unit comprises vitamin B12 and is formulated to provide elevated plasma levels of vitamin B12 for a period of at least 12 hours after ingestion.
30. The method of claim 26 wherein the third nutritional supplement dosage unit comprises vitamin B12 and is formulated to allow at least 15% of the vitamin B12 to dissolve in one hour in 900 ml of 0.1N HCl at 37° C.
31. The method of claim 26 wherein:
the first nutritional supplement dosage unit consists of two tablets or two caplets;
the second nutritional supplement dosage unit consists of two gel encapsulations; and
the third nutritional supplement dosage unit consists of one tablet or caplet.
32. The method of claim 31 wherein the five dosage unit elements of the first, second, and third dosage units are packaged in a common blister pack such that a day's complete dose is packaged together.
33. The method of claim 26 wherein the first, second, and third nutritional supplement dosage units are administered substantially simultaneously.
34. A nutritional supplement system for human subjects consisting essentially of:
a immediate release nutritional supplement dosage unit, the dosage unit being formulated to release one or more nutrients in the stomach of a human subject; and
a sustained release nutritional supplement dosage unit, the sustained release dosage unit being formulated to continually release one or more nutrients starting in the stomach and continuing into the upper intestinal tract of the subject, the one or more nutrients being selected from the group consisting of water-soluble nutrients and other nutrients that are typically very rapidly absorbed and are best delivered by sustained release so as to maintain an elevated concentration in the body over time.
35. The system of claim 34 wherein:
the immediate release nutritional supplement dosage unit comprises a plurality of vitamins and minerals and is formulated for immediate release in the subject's stomach; and
the sustained release nutritional supplement dosage unit comprises vitamin B12 and is formulated for sustained release of vitamin B12 starting in the stomach and continuing into the intestines of the subject.
36. The system of claim 35 wherein the sustained release dosage unit further comprises:
one or more additional B-vitamin(s); and
vitamin C.
37. The system of claim 34 wherein the sustained release nutritional supplement dosage unit comprises vitamin B12 and is formulated to provide elevated plasma levels of vitamin B12 for a period of at least 12 hours after ingestion.
38. The system of claim 34 wherein the sustained release nutritional supplement dosage unit comprises vitamin B12 and is formulated to allow at least 15% of the vitamin B12 to dissolve in one hour in 900 ml of 0.1N HCl at 37° C.
39. The system of claim 34 wherein:
the immediate release nutritional supplement dosage unit consists of two tablets or two caplets; and
the sustained release nutritional supplement dosage unit consists of one tablet or caplet.
40. The system of claim 24 wherein the three dosage unit elements of the immediate release and sustained release dosage units are packaged in a common blister pack such that a day's complete dose is packaged together.
41. A method for delivering nutrients to a human subject, the method comprising orally administering a nutritional supplement system consisting essentially of:
a immediate release nutritional supplement dosage unit, the immediate release dosage unit being formulated to release one or more nutrients in the stomach of a human subject; and
a sustained release nutritional supplement dosage unit, the sustained release dosage unit being formulated to continually release one or more nutrients starting in the stomach and continuing into the upper intestinal tract of the subject, the one or more nutrients being selected from the group consisting of water-soluble nutrients and other nutrients that are typically very rapidly absorbed and are best delivered by sustained release so as to maintain an elevated concentration in the body over time.
42. The method of claim 41 wherein:
the immediate release nutritional supplement dosage unit comprises a plurality of vitamins and minerals and is formulated for immediate release in the subject's stomach; and
the sustained release nutritional supplement dosage unit comprises vitamin B12 and is formulated for sustained release of vitamin B12 starting in the stomach and continuing into the intestines of the subject sufficient to provide elevated plasma levels of vitamin B12 for a period 12 hours after ingestion.
43. The method of claim 42 wherein the sustained release dosage unit further comprises:
one or more additional B-vitamin(s); and
vitamin C.
44. The method of claim 41 wherein the sustained release nutritional supplement dosage unit comprises vitamin B12 and is formulated to provide elevated plasma levels of vitamin B12 for a period of at least 12 hours after ingestion.
45. The method of claim 41 wherein the sustained release nutritional supplement dosage unit comprises vitamin B12 and is formulated to allow at least 15% of the vitamin B12 to dissolve in one hour in 900 ml of 0.1N HCl at 37° C.
46. The method of claim 41 wherein:
the immediate release nutritional supplement dosage unit consists of two tablets or two caplets; and
the sustained release nutritional supplement dosage unit consists of one tablet or caplet.
47. The method of claim 46 wherein the three dosage unit elements of the immediate release and sustained release dosage units are packaged in a common blister pack such that a day's complete dose is packaged together.
48. The method of claim 41 wherein the immediate release and sustained release nutritional supplement dosage units are administered substantially simultaneously.
49. A method for delivering nutrients and probiotics to a human subject, the method comprising:
providing one or more nutrients in the stomach of a human subject;
providing one or more nutrients in the upper intestinal tract of the subject, the one or more nutrients being selected from the group consisting of nutrients that do not require release in the stomach and exposure to stomach acid for efficient digestion and absorption and that cause tolerance problems or are subject to a loss in biological activity when released in the stomach;
continually providing one or more nutrients starting in the stomach and continuing into the upper intestinal tract of the subject, the one or more nutrients being selected from the group consisting of water-soluble nutrients and other nutrients that are typically very rapidly absorbed and are best delivered by sustained release so as to maintain an elevated concentration in the body over time; and
providing one or more supplement ingredients in the lower intestinal tract of the subject, the supplement ingredients being selected from the group consisting of nutrients and other supplement ingredients that are adversely affected by exposure to stomach acid or stomach digestion.
50. The method of claim 49 wherein:
the one or more nutrients provided in the stomach of a human subject comprise a plurality of vitamins and minerals that are immediate released in the subject's stomach;
the one or more nutrients provided in the upper intestinal tract comprise omega-3 fatty acids;
the one or more nutrients provided starting in the stomach and continuing into the upper intestinal tract comprise vitamin B12, and the vitamin B12 is provided in an amount sufficient to provide elevated plasma levels of vitamin B12 for a period 12 hours after ingestion; and
the one or more supplement ingredients provided in the lower intestinal tract comprise Lactobacillus acidophilus and Buifodobacterium longum.
51. The method of claim 50 wherein the one or more nutrients provided starting in the stomach and continuing into the upper intestinal tract further comprise:
one or more additional B-vitamin(s); and
vitamin C.
52. The method of claim 49 wherein the one or more nutrients provided starting in the stomach and continuing into the upper intestinal tract comprises vitamin B12 in an amount sufficient to provide elevated plasma levels of vitamin B12 for a period of at least 12 hours after ingestion.
53. The method of claim 49 wherein the one or more nutrients provided starting in the stomach and continuing into the upper intestinal tract comprise vitamin B12 and in an amount sufficient to allow at least 15% of the vitamin B12 to dissolve in one hour in 900 ml of 0.1N HCl at 37° C.
54. The method of claim 49 wherein:
the one or more nutrients provided in the stomach of a human subject are released from two tablets or two caplets that release nutrients in the stomach;
the one or more nutrients provided in the upper intestinal tract are released from two gel encapsulations that release in the intestinal tract;
the one or more nutrients provided starting in the stomach and continuing into the upper intestinal tract are released from one tablet or caplet; and
the one or more supplement ingredients provided in the lower intestinal tract are released from one layered tablet.
55. A method for delivering nutrients to a human subject, the method comprising:
providing one or more nutrients in the stomach of a human subject;
providing one or more nutrients in the upper intestinal tract of the subject, the one or more nutrients being selected from the group consisting of nutrients that do not require release in the stomach and exposure to stomach acid for efficient digestion and absorption and that cause tolerance problems or are subject to a loss in biological activity when released in the stomach; and
continually providing one or more nutrients starting in the stomach and continuing into the upper intestinal tract of the subject, the one or more nutrients being selected from the group consisting of water-soluble nutrients and other nutrients that are typically very rapidly absorbed and are best delivered by sustained release so as to maintain an elevated concentration in the body over time.
56. The method of claim 55 wherein:
the one or more nutrients provided in the stomach of a human subject comprise a plurality of vitamins and minerals that are immediate released in the subject's stomach;
the one or more nutrients provided in the upper intestinal tract comprise omega-3 fatty acids; and
the one or more nutrients provided starting in the stomach and continuing into the upper intestinal tract comprise vitamin B12, and the vitamin B12 is provided in an amount sufficient to provide elevated plasma levels of vitamin B12 for a period 12 hours after ingestion.
57. The method of claim 56 wherein the one or more nutrients provided starting in the stomach and continuing into the upper intestinal tract further comprise:
one or more additional B-vitamin(s); and
vitamin C.
58. The method of claim 55 wherein the one or more nutrients provided starting in the stomach and continuing into the upper intestinal tract comprises vitamin B12 in an amount sufficient to provide elevated plasma levels of vitamin B12 for a period of at least 12 hours after ingestion.
59. The method of claim 55 wherein the one or more nutrients provided starting in the stomach and continuing into the upper intestinal tract comprise vitamin B12 and in an amount sufficient to allow at least 15% of the vitamin B12 to dissolve in one hour in 900 ml of 0.1N HCl at 37° C.
60. The method of claim 55 wherein:
the one or more nutrients provided in the stomach of a human subject are released from two tablets or two caplets that release nutrients in the stomach;
the one or more nutrients provided in the upper intestinal tract are released from two gel encapsulations that release in the intestinal tract; and
the one or more nutrients provided starting in the stomach and continuing into the upper intestinal tract are released from one tablet or caplet.
61. A method for delivering nutrients to a human subject, the method comprising:
providing one or more nutrients in the stomach of a human subject; and
continually providing one or more nutrients starting in the stomach and continuing into the upper intestinal tract of the subject, the one or more nutrients being selected from the group consisting of water-soluble nutrients and other nutrients that are typically very rapidly absorbed and are best delivered by sustained release so as to maintain an elevated concentration in the body over time.
62. The method of claim 61 wherein:
the one or more nutrients provided in the stomach of a human subject comprise a plurality of vitamins and minerals that are immediate released in the subject's stomach; and
the one or more nutrients provided starting in the stomach and continuing into the upper intestinal tract comprise vitamin B12, and the vitamin B12 is provided in an amount sufficient to provide elevated plasma levels of vitamin B12 for a period 12 hours after ingestion.
63. The method of claim 62 wherein the one or more nutrients provided starting in the stomach and continuing into the upper intestinal tract further comprise:
one or more additional B-vitamin(s); and
vitamin C.
64. The method of claim 61 wherein the one or more nutrients provided starting in the stomach and continuing into the upper intestinal tract comprises vitamin B12 in an amount sufficient to provide elevated plasma levels of vitamin B12 for a period of at least 12 hours after ingestion.
65. The method of claim 61 wherein the one or more nutrients provided starting in the stomach and continuing into the upper intestinal tract comprise vitamin B12 and in an amount sufficient to allow at least 15% of the vitamin B12 to dissolve in one hour in 900 ml of 0.1N HCl at 37° C.
66. The method of claim 61 wherein:
the one or more nutrients provided in the stomach of a human subject are released from two tablets or two caplets that release nutrients in the stomach; and
the one or more nutrients provided starting in the stomach and continuing into the upper intestinal tract are released from one tablet or caplet.
67. An oral nutritional supplement dosage unit for use by a human subject wherein:
the dosage unit comprises vitamin B12; and
the dosage unit is a sustained release dosage unit that provides for sustained release of the vitamin B12, starting in the stomach and continuing into the small intestine of a human subject over a period of time.
68. A dosage unit of claim 67 formulated to provide elevated plasma levels of vitamin B12 for a period of at least 12 hours after ingestion.
69. A dosage unit of claim 67 formulated to allow at least 15% of the vitamin B12 to dissolve in one hour in 900 ml of 0.1N HCl at 37° C.
70. A dosage unit of claim 67 further comprising:
one or more additional B-vitamin(s); and
vitamin C.
71. A dosage unit of claim 67 comprising:
from 30 mg to 750 mg of vitamin C,
from 25 mg to 400 mg of calcium,
from 1 mg to 40 mg of vitamin B1,
from 1 mg to 40 mg of vitamin B2,
from 10 mg to 300 mg of vitamin B5,
from 1 mg to 40 mg of vitamin B6,
from 6 mcg to 500 mcg of vitamin B12,
from 1 mg to 100 mg of bioflavonoid complex, and
from 5 mg to 300 mg of quercetin.
72. A dosage unit of claim 71 formulated to allow at least 15% of the B-vitamins and vitamin C to dissolve in one hour in 900 ml of 0.1N HCl at 37° C.
73. A dosage unit of claim 67 that is in the form of a tablet or caplet.
74. A dosage unit of claim 73 further comprising an exterior film coating.
75. An oral nutritional supplement dosage unit for use by a human subject wherein:
the dosage unit is a tablet or caplet comprising
from 30 mg to 750 mg of vitamin C,
from 25 mg to 400 mg of calcium,
from 1 mg to 40 mg of vitamin B1,
from 1 mg to 40 mg of vitamin B2,
from 10 mg to 300 mg of vitamin B5,
from 1 mg to 40 mg of vitamin B6,
from 6 mcg to 500 mcg of vitamin B12,
from 1 mg to 100 mg of bioflavonoid complex, and
from 5 mg to 300 mg of quercetin; and
the dosage unit is a sustained release dosage unit that provides for sustained release of the vitamin B12, starting in the stomach and continuing into the small intestine of a human subject over a period of time sufficient to provide elevated plasma levels of vitamin B12 for a period of at least 12 hours after ingestion.
76. A method for the delivery of vitamin B12 to a human subject, the method comprising orally administering to a human subject a sustained release nutritional supplement dosage unit wherein:
the dosage unit comprises vitamin B12; and
the dosage unit is formulated to release the vitamin B12, starting in the stomach and continuing into the upper intestinal tract.
77. The method of claim 76 wherein the dosage unit is formulated to provide elevated plasma levels of vitamin B12 for a period of at least 12 hours after ingestion.
78. The method of claim 76 wherein the dosage unit is formulated to allow at least 15% of the vitamin B12 to dissolve in one hour in 900 ml of 0.1 N HCl at 37° C.
79. The method of claim 76 wherein the dosage unit further comprises:
one or more additional B-vitamin(s); and
vitamin C.
80. The method of claim 79 wherein the dosage unit is formulated to allow at least 15% of the B-vitamins and vitamin C to dissolve in one hour in 900 ml of 0.1N HCl at 37° C.
81. The method of claim 80 wherein the dosage unit is in the form of a tablet or caplet.
82. The method of claim 81 wherein the dosage unit has an exterior film coating.
83. A method for the delivery of vitamin B12 to a human subject, the method comprising orally administering to a human subject a sustained release nutritional supplement dosage unit wherein:
the dosage unit is a tablet or caplet comprising
from 30 mg to 750 mg of vitamin C,
from 25 mg to 400 mg of calcium,
from 1 mg to 40 mg of vitamin B1,
from 1 mg to 40 mg of vitamin B2,
from 10 mg to 300 mg of vitamin B5,
from 1 mg to 40 mg of vitamin B6,
from 6 mcg to 500 mcg of vitamin B12,
from 1 mg to 100 mg of bioflavonoid complex, and
from 5 mg to 300 mg of quercetin; and
the dosage unit is formulated to release the vitamin B12, starting in the stomach and continuing into the upper intestinal tract sufficient to provide elevated plasma levels of vitamin B12 for a period of at least 12 hours after ingestion.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/699,798 US20100143533A1 (en) | 2007-08-03 | 2010-02-03 | Nutritional supplement system |
US14/194,528 US9248095B2 (en) | 2007-08-03 | 2014-02-28 | Nutritional supplement system |
US14/983,268 US9763989B2 (en) | 2007-08-03 | 2015-12-29 | Nutritional supplement system |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95394407P | 2007-08-03 | 2007-08-03 | |
US95393407P | 2007-08-03 | 2007-08-03 | |
PCT/US2008/009399 WO2009020595A2 (en) | 2007-08-03 | 2008-08-04 | Nutritional supplement system |
PCT/US2008/009402 WO2009035496A1 (en) | 2007-08-03 | 2008-08-04 | Nutritional dosage unit |
US12/699,798 US20100143533A1 (en) | 2007-08-03 | 2010-02-03 | Nutritional supplement system |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/009399 Continuation WO2009020595A2 (en) | 2007-08-03 | 2008-08-04 | Nutritional supplement system |
PCT/US2008/009402 Continuation-In-Part WO2009035496A1 (en) | 2007-08-03 | 2008-08-04 | Nutritional dosage unit |
US14/983,268 Continuation US9763989B2 (en) | 2007-08-03 | 2015-12-29 | Nutritional supplement system |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/009399 Continuation WO2009020595A2 (en) | 2007-08-03 | 2008-08-04 | Nutritional supplement system |
US14/194,528 Continuation US9248095B2 (en) | 2007-08-03 | 2014-02-28 | Nutritional supplement system |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100143533A1 true US20100143533A1 (en) | 2010-06-10 |
Family
ID=40341943
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/699,798 Abandoned US20100143533A1 (en) | 2007-08-03 | 2010-02-03 | Nutritional supplement system |
US14/194,528 Active US9248095B2 (en) | 2007-08-03 | 2014-02-28 | Nutritional supplement system |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/194,528 Active US9248095B2 (en) | 2007-08-03 | 2014-02-28 | Nutritional supplement system |
Country Status (7)
Country | Link |
---|---|
US (2) | US20100143533A1 (en) |
JP (1) | JP2010535767A (en) |
CN (1) | CN101815509A (en) |
CA (1) | CA2695366C (en) |
MX (1) | MX2010001260A (en) |
TW (1) | TW200908892A (en) |
WO (2) | WO2009020595A2 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110200570A1 (en) * | 2010-02-04 | 2011-08-18 | Copperhead Chemical Company, Inc. | Composition and Method for Treating Infections and Promoting Intestinal Health |
US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
WO2015157428A1 (en) * | 2014-04-08 | 2015-10-15 | Mayo Foundation For Medical Education And Research | Ingestible capsule |
US20160073666A1 (en) * | 2014-09-16 | 2016-03-17 | New Chapter, Inc. | Supplement for a Breastfeeding Woman |
WO2016112170A1 (en) * | 2015-01-07 | 2016-07-14 | Corr-Jensen Inc. | Compositions and methods for enhancing athletic performance |
US20170071859A1 (en) * | 2015-09-16 | 2017-03-16 | Corr-Jensen, Inc. | Multi-phase release of sports nutrition and energy drink compositions utilizing lipid particulates |
EP3373908A4 (en) * | 2015-11-10 | 2019-04-24 | Probiotech LLC | Probiotic delivery systems |
US11523989B2 (en) | 2018-06-22 | 2022-12-13 | Probiotech Llc | Method to improve the health of the microbiome in a human gastrointestinal system and multi-chamber probiotic delivery products therefor |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010096564A2 (en) * | 2009-02-19 | 2010-08-26 | Probiohealth Llc | Dietary supplements containing polyunsaturated omega-3 fatty acids and probiotic bacteria with potential gastrointestinal and dermatological benefits |
WO2011099031A1 (en) * | 2010-02-11 | 2011-08-18 | Zota Health Care Limited | Active antioxidants for all age group |
CN102630779B (en) * | 2011-02-14 | 2015-07-22 | 三得利食品饮料株式会社 | Container-bottled drink for matching with quercetin glycoside |
EP2962578A1 (en) * | 2014-06-30 | 2016-01-06 | Richard Hubertus Verheesen | Method of providing a plurality of nutrition portions to a user and packaging product |
CA2951739C (en) * | 2014-07-01 | 2023-09-19 | Tntgamble, Inc. | Bi-layer dual release probiotic tablets |
US11291683B2 (en) | 2016-04-01 | 2022-04-05 | Access Business Group International Llc | Bilayer tablets of B vitamins and process for preparing the same |
EP3551292A4 (en) * | 2016-12-09 | 2020-08-05 | Balchem Corporation | Essential nutrients and related methods |
CN108836948B (en) * | 2018-06-11 | 2024-04-12 | 宁波西敦医药包衣科技有限公司 | Product capable of realizing controllable release of nutrients by coating technology |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3870790A (en) * | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
US5445826A (en) * | 1988-06-28 | 1995-08-29 | Cibus Pharmaceutical, Inc. | Delivery system containing a gel-forming dietary fiber and a drug |
US5494678A (en) * | 1992-09-23 | 1996-02-27 | Kv Pharmaceutical Corporation | Multi-vitamin and mineral supplement for pregnant women |
US5723446A (en) * | 1993-12-23 | 1998-03-03 | Nestec Ltd. | Enteral formulation designed for optimized nutrient absorption and wound healing |
US5843887A (en) * | 1994-09-01 | 1998-12-01 | Allied Medical Research Associates | Compositions for delivery of polypeptides, and methods |
US6451341B1 (en) * | 1990-02-05 | 2002-09-17 | Thomas J. Slaga | Time release formulation of vitamins, minerals and other beneficial supplements |
US20030148992A1 (en) * | 2000-03-27 | 2003-08-07 | Juergen Block | Sustained release vitamin composition |
US20040142036A1 (en) * | 1999-08-18 | 2004-07-22 | Abrams Andrew L. | Metering and packaging of controlled release medication |
US6805880B1 (en) * | 1999-08-20 | 2004-10-19 | Ferrosan A/S | Pharmaceutical delivery system for vitamin C and vitamin E and use of a combination of vitamin C and E for preventing or treating conditions involving oxidative stress |
US20060251722A1 (en) * | 2005-05-03 | 2006-11-09 | Novavax, Inc. | Multi-component vitamin and mineral supplement for the optimal absorption of components |
US20060270625A1 (en) * | 2005-05-13 | 2006-11-30 | Eastern Virginia Medical School | Nutraceuticals for the treatment of neuropathy |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0208362A1 (en) * | 1985-06-28 | 1987-01-14 | The Procter & Gamble Company | Dietary supplements containing iron and enterically coated calcium |
NZ217821A (en) * | 1985-10-10 | 1989-07-27 | Biotech Australia Pty Ltd | Oral delivery system; complex of active agent and vitamin b12 or analogue thereof |
JP2643222B2 (en) * | 1988-02-03 | 1997-08-20 | エーザイ株式会社 | Multi-layer granules |
CH680263A5 (en) | 1989-07-20 | 1992-07-31 | Norman Godin | |
AU646840B2 (en) * | 1990-02-05 | 1994-03-10 | Board Of Regents, The University Of Texas System | Dietary supplements comprising vitamins and minerals |
AU5252299A (en) * | 1998-08-04 | 2000-02-28 | Kv Pharmaceutical Company | Multi-vitamin and mineral supplements for women |
WO2002085415A1 (en) * | 2001-04-17 | 2002-10-31 | Biomatrix, Inc | Non-digestible sugar-coated products and process |
US6814983B2 (en) * | 2002-12-10 | 2004-11-09 | Everett Laboratories, Inc. | Compositions and methods for nutrition supplementation |
GB0403247D0 (en) * | 2004-02-13 | 2004-03-17 | Tillotts Pharma Ag | A pharmaceutical composition |
ITMI20042189A1 (en) * | 2004-11-16 | 2005-02-16 | Anidral Srl | COMPOSITION BASED ON PROBIOTIC BACTERIA AND ITS USE IN THE PREVENTION OF E-OR IN THE TREATMENT OF PATHOLOGIES AND-OR RESPIRATORY INFECTIONS AND IN THE IMPROVEMENT OF INTESTINAL FUNCTIONALITY |
-
2008
- 2008-08-04 WO PCT/US2008/009399 patent/WO2009020595A2/en active Application Filing
- 2008-08-04 CA CA2695366A patent/CA2695366C/en active Active
- 2008-08-04 JP JP2010519969A patent/JP2010535767A/en active Pending
- 2008-08-04 CN CN200880101810A patent/CN101815509A/en active Pending
- 2008-08-04 TW TW097129487A patent/TW200908892A/en unknown
- 2008-08-04 MX MX2010001260A patent/MX2010001260A/en unknown
- 2008-08-04 WO PCT/US2008/009402 patent/WO2009035496A1/en active Application Filing
-
2010
- 2010-02-03 US US12/699,798 patent/US20100143533A1/en not_active Abandoned
-
2014
- 2014-02-28 US US14/194,528 patent/US9248095B2/en active Active
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3870790A (en) * | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
US4389393B1 (en) * | 1982-03-26 | 1985-10-22 | ||
US5445826A (en) * | 1988-06-28 | 1995-08-29 | Cibus Pharmaceutical, Inc. | Delivery system containing a gel-forming dietary fiber and a drug |
US6451341B1 (en) * | 1990-02-05 | 2002-09-17 | Thomas J. Slaga | Time release formulation of vitamins, minerals and other beneficial supplements |
US5494678A (en) * | 1992-09-23 | 1996-02-27 | Kv Pharmaceutical Corporation | Multi-vitamin and mineral supplement for pregnant women |
US5723446A (en) * | 1993-12-23 | 1998-03-03 | Nestec Ltd. | Enteral formulation designed for optimized nutrient absorption and wound healing |
US5843887A (en) * | 1994-09-01 | 1998-12-01 | Allied Medical Research Associates | Compositions for delivery of polypeptides, and methods |
US20040142036A1 (en) * | 1999-08-18 | 2004-07-22 | Abrams Andrew L. | Metering and packaging of controlled release medication |
US6805880B1 (en) * | 1999-08-20 | 2004-10-19 | Ferrosan A/S | Pharmaceutical delivery system for vitamin C and vitamin E and use of a combination of vitamin C and E for preventing or treating conditions involving oxidative stress |
US20030148992A1 (en) * | 2000-03-27 | 2003-08-07 | Juergen Block | Sustained release vitamin composition |
US20060251722A1 (en) * | 2005-05-03 | 2006-11-09 | Novavax, Inc. | Multi-component vitamin and mineral supplement for the optimal absorption of components |
US20060270625A1 (en) * | 2005-05-13 | 2006-11-30 | Eastern Virginia Medical School | Nutraceuticals for the treatment of neuropathy |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110200570A1 (en) * | 2010-02-04 | 2011-08-18 | Copperhead Chemical Company, Inc. | Composition and Method for Treating Infections and Promoting Intestinal Health |
US8853269B2 (en) * | 2010-02-04 | 2014-10-07 | Copperhead Chemical Company Inc. | Composition and method for treating infections and promoting intestinal health |
US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
US8545896B2 (en) | 2011-09-29 | 2013-10-01 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
WO2015157428A1 (en) * | 2014-04-08 | 2015-10-15 | Mayo Foundation For Medical Education And Research | Ingestible capsule |
US20160073666A1 (en) * | 2014-09-16 | 2016-03-17 | New Chapter, Inc. | Supplement for a Breastfeeding Woman |
WO2016112170A1 (en) * | 2015-01-07 | 2016-07-14 | Corr-Jensen Inc. | Compositions and methods for enhancing athletic performance |
US20170071859A1 (en) * | 2015-09-16 | 2017-03-16 | Corr-Jensen, Inc. | Multi-phase release of sports nutrition and energy drink compositions utilizing lipid particulates |
WO2017048859A1 (en) * | 2015-09-16 | 2017-03-23 | Corr-Jensen, Inc. | Multi-phase release of sports nutrition and energy drink compositions utilizing lipid particulates |
EP3373908A4 (en) * | 2015-11-10 | 2019-04-24 | Probiotech LLC | Probiotic delivery systems |
US11523989B2 (en) | 2018-06-22 | 2022-12-13 | Probiotech Llc | Method to improve the health of the microbiome in a human gastrointestinal system and multi-chamber probiotic delivery products therefor |
Also Published As
Publication number | Publication date |
---|---|
WO2009020595A3 (en) | 2009-04-09 |
CN101815509A (en) | 2010-08-25 |
WO2009020595A2 (en) | 2009-02-12 |
CA2695366A1 (en) | 2009-02-12 |
CA2695366C (en) | 2016-10-04 |
JP2010535767A (en) | 2010-11-25 |
US9248095B2 (en) | 2016-02-02 |
MX2010001260A (en) | 2010-04-07 |
US20140178347A1 (en) | 2014-06-26 |
TW200908892A (en) | 2009-03-01 |
WO2009035496A1 (en) | 2009-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9248095B2 (en) | Nutritional supplement system | |
US9763989B2 (en) | Nutritional supplement system | |
AU2015284425B2 (en) | Bi-layer dual release probiotic tablets | |
US11278558B2 (en) | Synthetic composition for microbiota modulation | |
GB2212396A (en) | Dietary supplement comprising calcium and delayed release coated iron | |
KR20020031383A (en) | Oral form of administration containing probiotic micro-organisms | |
EA014825B1 (en) | Method for stabilising pharmaceutical administration forms that contain micro-organisms | |
CA2281463A1 (en) | Composition comprising micronutrients in combination with prebiotics, probiotics, and synbiotics | |
US20230218626A1 (en) | Methods and compositions to support the growth or maintenance of oxygen-sensitive bacteria in the gastrointestinal tract | |
CN116367823A (en) | Direct delivery of vitamins to inhibit microbial pathogens | |
JP2023016043A (en) | Gamma-polyglutamic acid and zinc compositions | |
US20210401900A1 (en) | Enteric composition, food or beverage product containing the same, method for controlling disintegration time of the same, and method for manufacturing the same | |
JPH11302158A (en) | Health food having intestinal function controlling action and produced by using enteric seam capsule | |
US20230404970A1 (en) | Direct delivery of vitamins to rebalance gut microbiome after exposure to antibiotics | |
WO2019243814A1 (en) | Dosage form comprising a live biotherapeutic product | |
WO2023237674A1 (en) | Vitamin b2 for use in improving gut health | |
WO2023237672A1 (en) | Vitamin b1 for use in improving gut health | |
JP2021014421A (en) | Qol improving agent | |
WO2023237683A1 (en) | Combinations comprising vitamin c and bacillus coagulans | |
WO2022091075A1 (en) | Combination compositions of probiotics with fermented wheat germ extract and uses thereof | |
CN117257845A (en) | Method for targeted delivery of live probiotics | |
CA2347891A1 (en) | Composition comprising micronutrients in combination with prebiotics, probiotics, and/or synbiotics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |